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Breast cancer i the most common type of cancer and the lead ing cause of cancer 
death among women in the Un ited Arab Emirate and a l l  over the world .  Although 
many factors contribute to the h igh i nc idence of breast cancer, a considerable number of 
case are related to environmental factors. In th is study, breast cancer was induced in 
female rats us ing a s ingle do e, 80 mglkg body wt of the envi ronmental carc inogen 7,12-
d imethylbenz[a]anthracene (DMBA). The aim was to characterize some of the early 
cel lu lar and molecular changes that occur during breast cancer development in the 
DMBA-treated rat model .  Mammary gland tissues of control and DMBA-treated rats 
were processed for: i) routine h i stological examination, to define the i nit ial 
h istopathological changes that occur in mammary gland t issues, i i) immunohistochemical 
probi ng using ant i -PCNA and anti-BRCA 1 ant ibodies to characterize and corre late the 
local ization of these cel l  cycle proteins during progression to cancer, i i i )  Western blott ing, 
to analyze the alteration of p53 prote in expression in pre-neoplastic and neoplastic lesions 
of the mammary glands, iv) polymerase chain reactions using primers specific  for PC A, 
BRCA 1 and p53 genes fol lowed by s ingle stranded conformational polymorphism 
(SSCP) or restriction fragment length polymorphism (RFLP) assays to detect poss ible 
mutations in these genes during development of breast cancer. 
M icroscopic  exam ination revealed a wide range of pre-neoplastic and neoplastic 
lesions in the mammary glands of DMBA-treated rats. They provided a sequence 
representing the mu lt istep process of breast cancer formation. The earl iest morphological 
change observed was moderate d i latat ion of the terminal ducts and accumulation of 
extruded dead cel l s  in their lumens. These changes were referred to as the stage of "ce l l  
death". I t  was fol lowed by stages of hyperplasia, dysplasia, and then in situ cribriform 
carc inoma. Final ly, the i nvasive cribriform and pap i l lary carc inomas developed. I n  
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addit ion, some DMB -treated rats developed benign tumors: lactating adenoma and 
quamou ce l l  pap i l loma. 
Immunoh i tochemical local ization of PCNA revealed an initial down regu lation 
during the stage of cel l  death fol lowed by a gradual increase in the number of PCNA­
labeled cel ls during the fol lowing stages of breast cancer development. Probing for 
BRCA 1 protein  suggested a gradual defect in its translocation from the cytoplasm to the 
nucleus during brea t cancer progression. In control rats, B RCA 1 was present in the 
nuclei  of termina l  duct epithe l ia l  ce l ls .  However, in the pre-neoplast ic lesions, B RCAI 
\ a loca l ized in both the cytoplasm and nucle i  of the epithe l ial duct cel ls .  I n  aU 
mal ignant l es ions, B RCA 1 was main ly found in the cytoplasm . 
Western blotting revealed that the expression of p53 prote in during breast cancer 
deve lopment was i n i t ia l ly down regulated.  However, with progression toward 
ma l ignancy, upregulat ion of the mutant form of p53 was observed . These changes were 
associated wi th polymorph ism i n  p53 gene, which was detected in exon 5 using SSCP 
a say. However, no polymorph i sms  were detected in the PCNA and B RCA ] genes. 
Because some recent studies suggested that the use of mult iple alkaloids may have 
some synergistic inhibitory influence on cancer ce l l  growth,  the effect of crude extract of 
Vinca alkaloids on the progression of breast cancer was tested in DMBA-treated rats . A 
dai ly  treatment of these rats wi th 200 mg/kg body wt of Vinca alkaloids for 2 1  days 
start ing 1 week after DMBA adm in istration i nduced about 50% decrease in the incidence 
of mammary gland neopl as ia .  When these tumors were compared with those of DMBA­
treated rats, the former were smal 1er i n  s ize, exhibited a smal ler number of PCNA-labeled 




in conclusion, characterization of the early change that occur during brea t 
cancer development may provide some clues for better understanding of its pathogenesi 
and wou ld hopeful ly improve modal i tie for i ts prevention and/or early detect ion . 
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INT RODUCTION & LITERAT URE R EVI E W  
Breast cancer i s  the most frequent type o f  cancer and the lead ing cause o f  cancer 
deaths in women worldwide ( mymiotis et aI . ,  2005) .  In the United Arab Emirates 
( AE), breast cancer is also the most frequent cancer among national females. 
According to UAE ational Cancer Registry in Tawam HospitaL 1 75 breast cancer cases 
out of 538  female can er cases (32 . 5%) were recorded from 1 998  to 2002 . 
I t  is wel l  known that the etiology of breast cancer is multifactorial . Many 
hormonal and nonhormonal factors contribute to the development of breast cancer 
(Martin and Weber, 2000). R i sk factors include both endogenous and environmental 
estrogens d iet and l i festyle, geographic area of residence, and age at menarche or 
menopause. However, in most cases there are no obvious causes of breast cancer, 
supporting the view that a variety of environmental carcinogens play a major role in 
i n it iation of the d isease (Steinetz et a I . ,  2006). 
Another important risk factor for the development of breast cancer is the positi ve 
fami ly h istory and genet ic influences (Martin and Weber, 2000) . The expression of some 
genes could be altered by mutations or ampl i fication wh ich therefore affect the ce l l  cycle 
and the normal control process of ceJ ]  pro l iferation (Hayes, 2000). Even though much 
has been revealed regarding these genes, but several questions remains to be answered 
regarding their expression in the commonly used animal models of breast cancer and their 
possible mutation. 
Introduction & Literature Review 
1.1 . A n i m a l  model  of breast ca ncer 
Due to comple ity of the factors in olved in breast cancer, many studie  have 
been conducted to elucidate its pathogenesis in the hope of providing some clues towards 
it earl detection, prevent ion and/or treatment. It is general ly agreed that animal models 
are the most useful tool to study breast cancer. These models have demonstrated the 
development of several types of breast neoplasms in animals comparable to those that 
occur in human . In these animals, breast cancer was induced by chemicals, rad iation, 
v i ruses or genetic manipu lations. Then, the pathogenesis of the d i sease including i ts 
in i t iation, promotion and progression was exam ined (Russo and Russo, 2000). 
everal animal models have been used to study breast cancer. The rat model has 
been common ly used because : ( i )  its mammary tumors, l ike those of humans, lack a 
major v iral etiology, ( i i) tumors i n  the rat can be rapidly induced by chemicals, and ( i i i )  
the rat mammary tumors resemble those of the human. Accord ingly, rat animal models 
have been considered as useful tools to examine preneoplastic, neoplast ic and metastat ic 
breast t i ssues. Furthermore, rat model can also be used to study genet ic alterations that 
occur early during tumor development (Sukumar et a I . ,  ] 995 ; Russo et aI . ,  ] 990c). 
I t  is wel l known that mammary glands are sensitive to exposure to X-rays. Based 
on this fact many investigators used radiation to induce mammary carc inogenesis in the 
rat. However the hormonal status of the rat is very important to determine the outcome 
of irrad iat ion. It has been shown that ovariectomy prevents rad iat ion-induced mammary 
tumors (Russo et aI . ,  ] 990c). 
The xenograft model has been developed by growing breast cancer cel l s  in nude 
m ice and found useful to test potential inhibitors of breast cancer cell growth (Long et a I ., 
2004) . I n  addition, genet ical ly engineered an imals, such as transgenic and knockout 
m ice have been found invaluable in defming and characterizing genes involved in breast , 
2 
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cancer. Introduc ing a foreign gene or deleting a normal gene in the mice has been useful 
to e am ine the role of pecific genes in mammary tumor de elopment and also to develop 
strategy for drug target val idation (Matulka and Wagner, 2005). 
For many mammary gland cel l  biologists, the chemical ly induced breast cancer by 
pol cyc l ic aromatic hydrocarbons, such as benzo(a)pyrene (B(a)P) and 7, 1 2-
d imethylbenz[a]anthracene (DMBA), has been the preferable model due to several 
reasons: I )  the re l iabi l ity of tumor induction, 2) organ target specificity, 3) tumors 
developed are mostly ductal (epithe l ial in origin), 4) the slowly developing tumor 
provides the potential to examine the early scenario that occur during tumor development 
(L iska et al. 2000), 5) the possible mutagenic effects of DMBA in the rat can alter some 
oncogenes (Sukumar at aI . ,  ] 995), and 6) DM BA-induced mammary tumors in rats have 
been considered as a good representation of those occurring in humans (Russo et aI . ,  
1 990b) . 
1.2. The stru cture of rat m a m mary gland 
10 female rats, s ix  pairs of  mammary glands are a l igned ventrolateral ly a long the 
mammary or m i lk l ines. The first pair of mammary glands is located in the cervical 
regIOn. The second and th ird pairs are found in the thoracic region, and the three 
remaining pairs, in the abdomino- inguinal region. Each mammary gland extends 
dorsolateraJ ly in a flat subcutaneous sheet of fibroadipose t issue (Russo and Russo, 1 978). 
M icroscopical ly, the mammary gland of adult v irgin rats is  composed of 
parenchyma and stroma. The latter includes a smal l amount of fibrous connective t issue 
surrounded by much adipose t issue. The parenchyma is made of a branching duct system 
which forms a tree- l ike structure. Close to the n ipple, one or two major lactiferous ducts 
3 
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branch into smal ler ducts that again branch and fmal ly term inate deep in the gland (Russo 
et a I . ,  1990c). 
The l in ing epithe l ium of the wal ls  of the major ducts is  variable.  ome areas are 
l ined by p eudostrati fied epithe l ium and others by simple columnar epithe l ial ce l ls. The 
wa l l s  of smal ler ducts and their term inal buds contain two main cel l  types: internal or 
lumina l  secretory cel l s  and external or peripheral myoepithel ia l  cel ls .  Whi le  the l um inal 
ce l l s  are joined by epithe l ia l  junctions to form a continuous layer, myoepithel ia l  cel ls are 
d iscontinuous ( Russo and Russo, 1 996) . 
1.3. Tu m o rs of rat m a m m a ry glan d  ind uced by D M BA 
DMBA-induced tumors do not occur randomly in the six pairs of rat mammary 
glands. V i rg in animals treated wi th DMBA between the ages of 45 and 5 5  days deve lop 
a greater number of tumors in mammary glands located in the thoracic  region than glands 
located in the abdomino-inguinal or cervical regions. Th is has been explained by the 
asynchroni sm of the development of the thorac ic mammary glands (Russo et aI ., 1 990b). 
1n these animals, the h igh suscept ib i l ity of the sma l l  and term inal ducts to neoplastic 
transformation is ascribed to the h igh pro l i ferat i ve act iv ity of their l in ing cel ls, as 
determined by m itotic and DNA-labe l ing i nd ices. These indices are maximal at the 
terminal smal l  ducts and decrease toward the major ducts of the gland (Russo and Russo 
1 987). 
Mammary gland tumors induced in rats by a single dose of DMBA comprise 
various ben ign and mal ignant forms (Russo et aI . ,  1 990c). It has been shown that each 
tumor could  be composed of a single h i stologic type or a combination of several patterns. 
Russo and Russo (2000) have c lass ified rat mammary tumors i nto d ifferent types based 
on thei r  m icroscopic  features. 
4 
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The earlie t h istological change ob erved in the mammary parenchyma after 
carcinogen adm ini tration is progres ive increase in the intraductal cel l  proliferation 
leading to enlargement of smal l  terminal ducts. Later, carcinoma in situ develops and 
fonns m i cropapi l lae and/or cribriform patterns. In the micropapi l lae type of ductal 
carc inoma in situ, the l ining epithe l ium of the di lated ducts grows inward, forming 
epithel ia l  pap i l lae with or without a thin fibrovascular core. Cells in th i s  lesion have 
un iform size and shape. But they are characterized by an increased nucleus/cytoplasm 
ratio and prominent nucleol i .  The cribri form type of ductal carcinoma in situ is 
characterized by accwnu lation of cel ls  in d i lated ducts with secondary l umens. 
Cytological ly, i t  appear to be s imi lar to the pap i l lary type (Russo and Russo, 2000). 
Invas ive papi l lary and cribriform carcinomas arise from in situ lesions, in which 
they di srupt the normal architecture of the gland, and invade the surrounding structures. 
In case of papi l lary carc inoma, the main features are secondary papi l lary project ions 
inc luding pleomorphic ce l l s  and serrated lumens. Cribri form carcinoma exhibits 
haphazard ly arranged, fmger- like epithe l ia l  projections into the surrounding stroma with 
moderate to marked pleomorph ic ce] ]s (Russo and Russo, 2000). 
Another form of mal ignant lesions is ductal comedocarcinoma. It is characterized 
by intraductal growth of epithe lia l lin ing. So, the ducts appear d istended and l ined by a 
mult i layered epithelium surrounding necrot ic debris (Russo and Russo, 2000). 
Ben ign tumors a lso develop in DMBA-treated rats. Lactating adenoma is the 
most common type.  This  tumor varies in size and i s  characterized by numerous glandular 
profiles with serrated lumens due to decapitat ion or supranuclear vacuol ization of the 
l in ing epithelium . These glandular lumens are usual ly distended with much secretion 
inside, wh ich may accumulate and lead to the formation of large cysts l ined w ith flattened 
epithe l ium (Russo and Russo, 2000). 
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1 .4. Mecba n i  m of DMBA-i nd u ced b reast ca n cer 
It is well e tablished that a single dose of DMBA results in a high yield of 
mammary tumor in rats. DMBA is most effective in the induction of tumors when 
admini tered to rats at 50-56 days of age ( inha et aI., 1 983) .  This optimal window of 
su ceptibility to tumor i probably due to the active proliferation of the terminal ducts 
during thi period (around 7-8 weeks of age) .  Therefore, mammary glands of virgin rat 
are more susceptible to tumorigenesis by chemical carcinogens than mature and 
differentiated glands (Ariazi et a!., 2005). 
DMBA is a ynthetic, polycyclic aromatic hydrocarbon. Fol lowing its 
admin istration the concentration of DMBA in the whole mammary gland is 1 1 0-fold 
higher than that obtained from collagenase-dissociated mammary epithelial cells. 
Therefore. it seems that mammary fat pad serves as a reservoir for sustained release of the 
procarc inogen into the parenchymal tissues. This phenomenon explains the great 
susceptibility of the mammary epithelial cells to carcinogenesis by D M BA (Menon et a!., 
1 987).  
Radioautographic studies using eH]-DM BA have demonstrated that within the 
mammary epithelium the highest uptake of DMBA occurs in the nuclei of cells lining the 
small terminal ducts. This indicates that DMBA binds to the structures of the gland with 
the highest proliferative activity. Following i ts binding, DMBA causes up-regulation of 
the cellular cytosolic receptor, the aryl hydrocarbon receptor (Trombino et aI., 2000). 
Then, aryl receptor-dependent up-regulation of cytochrome P450 occurs. Finally DMBA 
gives rise to polar and phenolic metabolites as well as the active compound, 3,4-diol-l,2-
oxide. The latter interacts with cellular DNA and forms different adducts that cause 
m utations and tumor in i tiation (Rundle et a!., 2000). 
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1.5. Gene i nvolved in breast cancer 
Advances in cel l u lar and molecu lar biology techniques have made it pos ible to 
c larify much of th basic ce l lu lar and molecular events leading to cancer. Many gene 
have been found to play a role in the development of cancer. They are c lassified into 
three major categories: tumor suppressors oncogenes and DNA repair genes (Jorde et aI . ,  
2000). In case of breast cancer, tumor suppressor genes, such as P53 and B RCA 1 ,  are 
found to be frequently involved in its development (lngvarsson, 1 999). 
1.5.1. P53 
I n  humans, P53 is located on chromosome 1 7p (Levine et. aI . ,  1 99 1 ). The normal 
a l le le  of this autosomal gene encodes a 53 kD nuclear protein (Hol lstein et a I . ,  1 99 1 ), 
which consists of at least three domains: a transactivation domain at the NH2 terminus; a 
central specific DNA binding domain; and an ol igomerization domain at the COOH 
terminus (Zhang et a J .  2000). In addit ion to the main function of P53 as a guardian of 
genome, it also appears to function in the regu lation of various ce l l  biological processes: 
ce l l  cyc le and growth, ceU death, signal transduction, and gene expression (Hu l la and 
Schneider, 1 993) .  
Whi le the wi ld-type p53 protein suppresses ce l l  growth, the mutated form acts as 
an oncogene .  Mutations in the P53 gene usual ly result in stabi l ization and accumulation 
of i ts expressed protein (Sarbia et a I . ,  1 994) .  I ncreased levels of p53 protein were found 
in a high percentage of mal ignant tumors but only rarely in benign tumors and normal 
t issues (porter et aI., 1 992). 
It has been estimated that up to 58  % of breast cancer patients have mutated P53 
gene with accumulation of altered p53 protein, which can be detected by immunological 
assays (Lipponen et aI., 1 993 ;  E l ledge and Al l red, 1 994). 
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The mutational spectrum of p53 d iffers according to the type of cancer. In breast 
cancer, G to T tran ver ion is more commonly seen. I nduction of such a single point 
mutation re ults in a change of conformation, increased protein stability, and marked 
changes in i ts function. Most mutant forms of p53 lose the ability to bind to DNA and 
cause abnonnal cell growth (Bargonetti et aI . ,  1 99]; Raycroft et aI . ,  1 99 1 ;  Dittmer et aI ., 
1 993) .  Moreover, it has been shown that the p53 abnormalit ies correlated with the grade 
of cancer and advanced with tumor growth (Teramoto et a!., 1 994). 
Using a panel of human breast cancer cell lines, it has been shown that the large 
amounts of the mutant p53 proteins are due to their much longer half- l i fe than that of the 
wi ld-type protein (Levi ne et a1 . ,  1 99 1 ) . Mutant forms of p53 was also found to bind to 
the endogenous wild-type p53, forming tetrameric complexes, which caused stabi l ization 
of the rapidly degraded wild-type protein and inactivation of i ts suppressor function by 
altering its confIrmation (Milner and Medcalf, 1 99 1 ;  Kaklamanis et aI., 1 993).  
In the rat, P53 gene has 1 0  exons and 9 introns, whereas mouse or human P53 
gene contains 1 1  exons. In addit ion, rat P53 gene lacks sequence corresponding to intron 
6 indicat ing that this sequence is nonfunctional in species that retain it (Hulla and 
chneider, 1 993) .  However, P53 gene conservation has been found to be s imi lar in size 
of the exons, introns and locations of splice junctions. The majority of the missense 
mutations are located at codons correspond ing to amino acids conserved in human, 
monkey, rat, mouse, chicken, xenopus, and fish (Hollstein et aI., 1 99 1 ). 
1.5.2. BRCAl 
I n  h umans, B RCA I gene is located on chromosomes 1 7q 1 2-2 1 and produces 
protein of 1 863 amino acid (:::::220 kDa). I t  contains 24 exons (22 coding and 2 non­
coding) and covers a span of::::: 1 00 kb of genomic DNA .  The B RCA 1 coding region 
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comprises ::::::5 .5 kb. In  addition to the full length of 8 kb mRNA transcript has been 
identified various smaller BRCA I transcripts with tissue specific expression pattern have 
also been de cribed (Rosen et aI . ,  2003).  
B RCA 1 protein interacts with other nuclear proteins, such as Rad5 1 and B RCA 2 
( cully et aL, 1 997· Chen et a1 . ,  1 998), and consequently plays several critical functions 
in the cell. I ts amino terminal ring fmger domain is involved in: repression of estrogen 
receptor-a signaling modulation of DNA repair, and apoptosis. The carboxyl terminal 
acidic domain of BRCA l acts as transcriptional activation domain when linked to DNA 
binding domain. Moreo er, B RCA I plays a role in cell cycle checkpoints and proper 
replication and functioning of centromeres ( Rosen et al. , 2003). 
I ndividuals carrying mutations in the BRC A l  gene have an increased risk of 
developing breast and ovarian tumors (Smith et aI . ,  1 992). M utations in BRCA I alone 
account for approximately 45% of families with high incidence of breast cancer and up to 
80% of families with both breast and ovarian cancer (Easton et aL, 1 993). I t  has been 
shown that B RCA 1 knockout mice are hypersensitive to ),-irradiation which induces 
chromosomal aberrations (Shen et a1., 1 998).  Therefore, loss of transcription activation 
by B RCA I is an important factor in oncogenesis. 
B RCA 1 germline mutations account for most hereditary breast cancers. However, 
B RCA I is mostly related to tumors diagnosed before age 40 years (Ottini et aL, 2000). 
No somatic m utations have been detected in sporadic breast cancer, but other alterations 
were reported such as loss of heterozygosity, decreased levels of the BRCA I m RN A ,  and 
methylation of the BRCA 1 promotor region. Accordingly, B RC A 1  is involved in breast 
neoplasias of sporadic origin and the magnitude of its decreased expression correlates 
with disease progression (Yoshikawa et aL, 1 999; M ueller and Roskelley, 2002; Fraser et 
aL, 2003). 
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In rat , it ha been shown that BRCA 1 sequence is highly homologous to that of 
mou e (88%) and human (8 1 %) with the highest homology in the region (nucleotide 5 1 -
1 73 )  encoding the ring-finger domain (Chen et al. , 1 996). This domain is a zinc binding 
motif that facilitate interaction between BRCA I and other proteins to perform several 
function uch as DNA repair and ubiquitination (Fang et aI., 2003). The ring-fmger 
domain is 94% identical to the mouse sequence and 89% to the human . 10 addition to the 
homology in ring-finger domain among mammalian species, nuclear localization signals 
in rat are also identical to those of human and mouse. Analysis of BRCA 1 rat promoter 
revealed that it shares 90% and 68% identity with the mouse and human sequences, 
respectively (Bennett et aI., 1 999). 10 some rat models of breast cancer, it has been 
shown that while B RCA 1 m RNA level does not change, allelic imbalance of BRCA 1 
may occur (Chen et a I . ,  1 996). 
There is a controversy regarding the localization of BRCA] protein 10 the 
m ammary gland, Some investigators reported that it is found in the nuclei of nonnal 
epithelial cells, but is aberrantly located in the cytoplasm of malignant mammary cells 
(Chen et aI., 1 995). However, the expression of BRC A I  protein in the nuclei of both 
normal and malignant cells was demonstrated (Scully et aI., 1 996). Also, the localization 
of B RCA 1 in cytoplasm and the cell membrane was reported (Jensen et aI., 1 996). The 
localization of B RCA 1 protein in cytoplasmic tube-like invaginations in the nucleus was 
also reported (Coene et aI ., 1 997). These contrarieties on the location of B RCA 1 protein 
were interpreted as differences in the specificity of the antibodies or fixation protocols 
used, or as evidence for the presence of splice variant isoforms of the BRCA 1 protein in 
tumors (perez-Valles et aI., 200 1 ) . 
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1.6. Potent ia l  breast cancer preventive agents 
]t ha been reported that some factors may influence the development of breast 
cancer. Earl full-term pregnancy significantly lowers a woman's risk of de eloping 
breast cancer (peck et a I . ,  2002). This association between pregnancy and reduced breast 
cancer risk has been validated in experimental studies which have shown that pregnancy 
protects rats against carcinogen-induced mammary cancer. Therefore, it seems that pre­
neoplastic cells present in the mammary glands prior to pregnancy are either destroyed or 
altered during pregnancy by hormone induced differentiation of the glands (Thordarson et 
al., 1 995) .  
Dietary factors have been an appealing approach for the prevention of breast 
cancer. Naturally occurring coumarins represent one of the largest classes of 
phytochemicals. These compounds are found in many plants and had a greater inhibitory 
effect on the formation of D MBA-DNA adduct in mouse mammary glands (Prince et aI., 
2005).  In addition, a natural isoflavonoid phytoestrogen found in soy products 
"genistein", is thought to possess breast cancer preventive properties. It has been shown 
to provide some protection against DMBA-induced mammary tumors in rats 
(Lamartiniere et al., 1 998) .  
Recently, the anti-malarial compound called "artemisinin", which was isolated 
from the sweet wormwood Artemisia annua L., has been shown to have a significant 
preventive effect on breast cancer development in DMBA-treated rats (Lai and Singh, 
2006). 
Vinca alkaloids are natural compounds which are present in the plant called 
Catha/anthus rose us G. Don (or Vinca rosea Lin, or periwinkle; Fig. 1 ) . Catharanthus 
roseus contains about 90 different alkaloids, some are indole monomeric while others are 
dimeric alkaloids.  Some of these alkaloids, such as vincristine, are commonly prescribed 
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Fig. 1 :  Catharanthus roseus or Vinca rose a whole plant. 
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for cancer chemotherapy (Rowin ky and Donehower, 1 99 1 ;  Ali, 1 998; Murata and 
DeLuca 2005). 
Vinca alkaloids molecule is composed of two parts: a large multiple ring structure 
called catharanthine (the upper half of the Vinca structure) and lower multiple ring 
domain called vindoline. I t  has been shown that the catharanth ine ring is responsible for 
the binding of the Vinca alkaloids to tubulin molecules and the vindoline ring enhances 
the binding process and interferes with tubulin polymerization (Budman, 1 992) .  I n  
add ition to the ir  blocking effect o f  m icrotubule assembly and cell cycle progression in the 
G2-M phase, Vinca alkaloids has been recently shown to induce apoptosis via its effect 
on A P I  transcription factor (Fan et aI. ,  200 1 ). 
In I nd ia  and some other countries, leaves and flowers of Vinca rose a are being 
used tradit ionally by some patients.  There have been some experimental trials on the use 
c rude extract of Vinca rosea as a potential ant i -cancer cell agent and promising results 
were reported. M ice carrying the Ehrlich ascites carcinoma cells and treated w ith the 
crude roseus extract showed a 46% reduction in cancer cells (Rana et. a I ., 2004). Studies 
have shown that such crude extracts are not toxic in rats (S ingh et aI . ,  200 1 ). Other 
studies on the extracts of leaves and twigs of Vinca rosea also indicate very h igh margin 
of safety (Chattopadhyay et a I . ,  J 992; Chattopadhyay, 1 99 1 ) . 
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A I MS OF THE STUDY 
The 0 erall bjecti e of this stud was to characterize the early change that 
occur during breast cancer progression in DMBA-treated rats and to test whether 
treatment with a crude extract of Vinca alkaloids could alter these changes. Therefore, 
the pecific aim of the present study were to util ize the DMBA-treated rat model to: 
1. characterize the basic m icroscopic changes that occur during breast cancer 
development, with special emphasis on the early stages, using routine 
histological techn iques. 
2. correlate the histological changes that occur during breast cancer development 
\ ith the changes in cell proliferation by using antibody specific for the 
proli ferating cell nuclear antigen (PCNA) as a marker for dividing cells. 
3. analyze the expression of protein products of two tumor suppressor genes, P53 
and B RCA I ,  in the mammary glands during the d ifferent stages of breast cancer 
development by using immuohistochem istry and western blott ing techniques. 
4. test whether mutations occur in  P53,  BRCA I ,  and PCNA genes during breast 
cancer deve lopment by using single strand conformation polymorphism (SSCP) 
and restriction fragment length polymorphism (RFLP) assays. 
5. study the effect of the crude extract of alkaloids of Vinca rosea on the inc idence 
of pre-neoplastic and neoplast ic lesions in the mammary glands by using 
morphological techn iques. 
6. examine whether Vinca alkaloids has an effect on the P53, B RCA 1 ,  and PCNA 
at the level of proteins and DNA during breast cancer development by using 
immunohistochemistry, western blott ing, SSCP, and RFLP assays. 
CHAPTER II 
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MAT E R I A L  AND METHODS 
II.I. Extraction of crude a lka loids from Vinca rosea 
The crude e tract of alkaloids was prepared according to the protocol published in 
the te tbook of Physicochemical tandards of Unani Fonnulations (Central Council For 
Research I n  Unani Medicine, 1 987). All chemicals used for extraction of alkaloids were 
purcha ed from igma ompany (U A) .  The aerial parts of virgin Vinca rosea (which 
ha no flowers yet) were collected from the nursery of AI-Am municipality between 
eptember and ovember, 2003. Collected plants were washed thoroughly with tap 
water followed with distilled water and were shade dried. About 1 00 gm of dried plant 
material was incubated with 2 liters of 0 .5N H2S04 for 20 min at room temperature. 
After filtration, acid treatment was repeated 3 times. The pH of the acid extract was 
raised to about 1 2  by adding 50% NH40H with shaking in separating funnel containing a 
mix of chlorofonn and ether (2: 1 ) . All chlorofonn-ether extract was pooled out and then 
haked with different volumes ( l 00, 50, 50, 25 ml) of 0 .5N H2S04 for complete 
extraction.  Combined acid extract was filtered and its pH was checked alkaline to litmus 
with the ammonium hydroxide solution. The liberated alkaloids were extracted with 
successive portions ( J  00, 5 0, 50, and 25ml) of chlorofonn to ensure complete extraction. 
The combined chloroform extract was washed with 50 ml of water twice. Chloroform 
was distilled off on a water bath and removed completely in vacuum desiccator. Five 
miJlilitres of 90% alcohol was added to the residue and the solvent was again removed. 
Evaporation with alcohol was repeated, and the residue was dried in vacuum desiccator 
and the weight was taken as total alkaloids. Figure 2 shows the extracted crude alkaloids. 
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Fig. 2 :  Crude extract of alkaloids prepared from the aerial parts of virgin Vinca roseo. 
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1 1 . 2. A n i m a l  
Female virgin Wistar rats (43-50 days old) were lIsed i n  this study. Rats were 
upplied by the Animal House of the Facu lty of Medicine and Health c iences, UAE 
Univer ity UAE. Al l  rat were kept in standard conditions with regimen l ight-dark: 1 2-
1 2  hr and received food and water ad libitum. 
II .3. Prepa rat ion o f  D M BA solution 
For induction of breast cancer, freshly prepared solution of DMBA ( igma, USA) 
was used . A bout 0.3 gm of DMBA was suspended in 40 ml  com oil ,  and then heated in a 
water bath at -95°C for 30  minutes with mixing by a glass rod. When the solution 
became c lear, with no v isible partic les of DM BA, it was cooled to room temperature and 
immediate ly administered into rats. 
I I .4. E x pe rimenta l d es ign 
Three groups of rats were used in this study. The first group contained 2] rats 
which were used to induce breast cancer by intragastric treatment with DMBA solution as 
a single dose of 80 m glkg body weight (Russo and Russo, 1 996).  The second group 
inc luded 20 rats which were treated with DMBA as in the fust group, but one week later, 
they received a daily oral dose of crude a lka loid extract (200 mglkg body weight) 
suspended in 5 0% polyethylene glycol 600 (Fluka., Switzerland) for three weeks. The 
third group, inc luded 9 rats and was served as age-matched control and received com oil 
on ly. 
A l l  rats were examined weekly to detect any changes in the general physical 
activity and body weights. I n  addition, the manunary glands were gently palpated to 
detect early development of any abnormal mass. 
Material and Methods 
Rats in each group were chosen random l and k i l led by an overdose of anesthetic 
after 25 30 3 5  or 40 weeks from the beginning of treatments. For each rat, the 
mammary gland of one ide , ere immediately d is ected and stored at -80°C for D A 
e traction and protein analysis. The opposite l ine
. 
of mammary glands were d issected 
along with skin pe lt, imm ediate ly immersed overn ight ( 1 2-24 hI) in Bouin 's  solut ion. 
The Bou in's fixative was made of 70% picric ac id solution, 1 0% formaldehyde, and 5% 
acetic acid .  F ixed tis ues were then processed for dehydration in  ascending grades of 
alcohol, c learing in xylene and paraffm infiltration and embedding. Paraffin t issue blocks 
\ ere cut at 5 11m thickness, mounted on gelatin-coated glass sl ides and then used for 
histopathological and immunohistochemical studies. 
In ca e that a mammary gland had a mass or tumor, it was weighed and d iv ided 
into two equal parts. One part was processed for histopathological and 
immunohistochemical studies, and other part, for DNA and protein  analyses. 
IT .S. H istopathological  s tudies 
Mam mary gland t issue sections of control and treated rats were processed for 
routi.ne hematoxyl in  and eosin (H&E) staining as fol lows. Sections were dewaxed in 
xylene twice (5 m in each), then rehydrated with descending grades of alcohol .  Sections 
were then stained with Harris hematoxyl in  for 30 m i n, washed in tap water for a few 
seconds, and dipped in 1 % hydrochloric acid  in  alcohol. Sections were then kept in tap 
water for 5 m i n  fol lowed by sta in ing with eosin Y for 25  second. Final ly, sections were 
dehydrated, cleared in xylene, and mounted with DPX medium. 
Stained t issue sections were exam ined with Olympus l i ght microscope to defme 
the histopathological changes in the m ammary glands and to c lassify tumors according to 
prev iously establ ished criteria (Russo et. al 1 990b· Russo and Russo, 2000) . 
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II.6. Im m u n o h istoc h e m ica l t u d ie 
Paraffin tis ue section obtained from control rats and their age-matched DMBA­
treated and DMBA-plus-alkaloid -treated rat were mounted on the same sl ides. Tissue 
ection were deparaffinized in ylene, rehydrated in descend ing grades of a lcohol ,  and 
washed in pho phate buffered sa l ine ( PBS).  To inhibit endogenous peroxidase activity, 
ection were i ncubated in 1 % hydrogen peroxide in methanol for 30 m in .  The sl ides 
were placed horizonta l ly in a humid chamber. To ensure equal conditions on all t issue 
sect ions to be probed, sl ides were drained off, area around sections were wiped dry, and 
c ircled \ ith a th in fi lm u ing PAP-pen (Dako, Denmark) .  Nonspecific bind ing was 
blocked by incubating sections in 1 %  bovine serum albumin contain ing 0 .5% Tween-20 
in PB for 45  m in .  Then, sections were i ncubated with the primary antibody for 
overnight at 4°C .  
The first primary antibody used was mouse monoclonal anti-PCNA antibody 
(clone 5A l O, d i l ut ion 1 : 1 00, Med ical and B iological Laboratories Co., Japan). Sections 
were washed 3 t imes with PB , 3m in  each,  and then incubated with biotinylated donkey­
ant i-mouse immunoglobu l in  JgG (d i lut ion 1 : 800 Jackson lmmunoResearch Laboratories 
Inc. ,  USA) for 30 min .  Fol lowing three PBS washes, sections were incubated in 
extravid inJperoxidase conjugate (d i lution 1 :  1 000, S igma, USA) for 1 hOUT. The ant igen­
ant ibody binding s ites were revealed by incubating t issue sections with 3, 3 ' ­
diaminobenz id ine tetrahydrochloride (DAB, S igma, USA). Development of the colour 
was stopped after 35 min  by washing the sections twice with d isti l led water (Smin each). 
Tissue sections were counterstained with periodic acid Sch iff (PAS) technique. 
Briefly, periodic acid (0. 5%) was added to the t issue sections for 1 0  min, fol lowed by 
wash ing i n  tap water. Then Schiffs  reagent (BDH Laboratory suppl ies, UK) was added 
for 20 min .  Sections were washed using tap water for 1 5  min.  Final ly, sections were 
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dehydrated through graded alcohol cleared in x lene and mounted using DPX. egative 
control l ides were prepared in paral lel without adding the primary ant ibody. 
To measure the intensity of PCNA immunolabel ing of the cel ls, image analysis 
was performed using Scion l mage Beta 4 .02 software for Windows 
(http://www .scionimage.com/). To m in imize possible d i fferences among t issues a l l  
ections used for measurements were placed on the same sl ide, and subjected to the same 
tain ing procedure . Probed ections were exam ined at h igh magn ification (x640) and 2-
3 fie lds were photogTaphed with d igi ta l  camera at the same condit ions and used for 
measurement. Cells cut through the center of their nuclei were only considered for 
measurement. Fol lowing measurement of sta ining intensity of the various nuclei in one 
section, the background intensity was measured and subtracted . Quantitat ive results of 
the optical density were reported in arbitrary units corresponding to DAB sta in ing 
intensity wh ich was taken as an indication of the amount of PCNA in the sectioned cel ls .  
The measurements were presented as means of arbitrary units ± standard error of the 
mean (SEM).  
To estimate the label ing index (L1) of PCNA immunostain ing, for each mammary 
gland, images of at least three fields at x640 magnification were random ly selected from 
2 or more rats. The total number of PCNA-Iabeled ce l ls  per high power field was 
counted . Data were expressed as mean ± SEM. 
The student t test (S igmaPlot for Windows, version 9 .0) was used to examine the 
d ifferences in labe l ing intensity and label ing index in control and treated rats. P<O.OS 
was considered to be stat ist ical ly s ignificant. 
The second primary ant ibody used was to study cel l u lar expression of B RCA l .  
The rabbit poJyc lonaJ ant i -BRCA l antibody (c lone I -20, Santa Cruz B iotechnology Inc. ,  
U SA )  speci fic for the C-term inal region between codons 1 823- 1 842 (Schofied et aJ . .  
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2000) wa u ed. In addit ion the catalyzed signal ampl i fication kit (C A kit, Dako 
Denmark) was u ed. tain ing procedure were carried out accord ing to the 
manufacturer's in tructions. Briefly, sections were fi rst incubated for 5 min ith 3% 
h drogen peroxide to suppress endogenous peroxidase activ ity. Then, prote in block was 
added for 5 min to pre ent nonspecific  binding. Ant i-BRCA I antibody was d i luted at 
1 : 50  and added for overnight at 4°C .  Sections were washed with TBST (50mM Tris-HCl 
PH 7.6, 300mM aC I ,  0. 1 % Tween-20) three t imes, 3 min each.  Biotinylated donkey-
anti -rabbit IgG (Jackson l rnmunoResearch Laboratories I nc .  USA) was then added at 
d i lut ion 1 : 500 for 1 5  min .  Sections were washed with TBST and streptavid in-biotin 
solution was added for 1 5  m in .  After washing, ampl ification reagent was added for 30 
min,  fol lowed by washing and applying streptavidin-peroxidase reagent for 1 5  min .  
Final ly. substrate-chromogen solut ion was added, and the development of the  brown 
colour was monitored by m icroscope. Colour deve lopment was stopped by adding 
disti l led water (twice, S m in each). Sections were counterstained with Harris hematoxyl in  
for 5 min  and then washed in tap water and d ifferentiated in acidic alcohol . Tissue 
sections were then kept in water for 5 min.  F inal ly sections were dehydrated through 
ascending grades of alcohol, c leared and final ly mounted on glass sl ides using DPX. 
egat ive control s l ides were prepared in  paral le l  without adding the primary ant ibody. 
I I .7 .  Sod i u m  dodecyl s u l p ha te-polyacry la m ide gel electrophoresis (SDS-
P A G E) a n d  Western blot a n a lysis 
The whole mammary gland tissues of control and treated rats were homogenized 
into a powder under l iqu id n itrogen temperature and then lysed with 1 ml buffer
 
containing: 1 00 mM 4_(2_hydroxyethyl)- 1 -piperazineethanesul fon ic acid ( HEPES
, PH 
7.5) ,  1 0% sucrose, 1 0  m M  1 4-Dith io-DL-threitol (DIT), 0. ] % 
3- [ (3-, 
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cholamidoprop I)dimeth I -ammoniol ] - I -propanesu lfonate (CHAP ), 1 50 mM aCL and 
prote in inhib i tors : 1 00 ruM phenylmethylsulfonyl fluoride (PMSF), 0. 1 % leupeptin and 
aprotenin .  Ti ssue I sate were centrifuged at 1 4 000 rpm for 30 min at 4°C .  Protein 
concentrations in the supernatants were detennined according to the method of Bradford 
( 1 976) u ing the B ioRad protein assay kit (B ioRad Laboratories, USA). 
Equal amounts of protein (30 /-lg) from each ample were m ixed with 5x sample 
buffer containing Tris HCl (PH 6.8), 1 0% glycerol, 2% sodium dodecyl su lphate, 2-
mercaptoethanol, and bromophenol b lue .  Samples were boi l ed for 5 min and 
e lectrophoresed on 8% polyacrylamide gel at 80 volts for 2 hours. To check the expected 
size of the protein, prestained prote in marker (BioRad Laboratories, USA) was used . 
After e lectrophoresis, prote ins in  the gel s  were trans blotted onto n itrocel lu lose 
membrane.  Non-specific  binding was blocked by 5% non-fat dry m i lk in PBS containing 
0. 1 % Tween-20 (PBST) for 1 hour. Fol lowing washing in PBST two times 1 0  min each 
blots were incubated with mouse monoclonal anti-p53 antibody (clone PAb240, d i lution 
I :  1 000. Dakocytomation, USA) for overnight at 4°C .  After rinsing with PBST (two 
times, 1 0  m in each), blots were incubated with horseradish peroxidase-conjugated goat­
anti-mouse IgG (Ce l l  S ignal l ing Technology, USA)  at d i lution 1 :  1 000 for 2 hours at room 
temperature. Blots were then washed with PBST three times for 1 0  min each, and 
immunoreactive prote ins in the blot were detected using enhanced chemi luminescence 
(ECL) western blotting detection reagents (pierce B iotechnology, USA) on Fuj i  medical 
X-Ray film (Japan). To confirm equal load ing of proteins, same blot was immunoprobed 
with rabbit  polyclonal anti-actin antibody (di lut ion 1 : 1 000, c lone AC40, S igma, U SA). 
F i lms were scanned using BioDocAnalyze system (B iometra, Germany), and the intensity 
of bands was measured. 
Material and Method 
I I .S .  Extraction of D N A  
Genomic D A wa btained from mammary glands of control and treated 
animal u ing DNA extraction kit (QIAGE , Canada). Tissues were quickly ashed in 
cold PBS,  weighed, and then homogenised in a mortar at  l iquid n itrogen temperature. 
The fine powder wa mixed with steri le/cold PBS ( 1 00 /-ll PBS for each 20 mg of the 
t i s  ue). Homoginized t i ssue was m ixed with equal amount of d igestion buffer provided 
b the k i t .  Q lAamp column conta in ing DNA was transferred to clean eppendorf tube. 
and 50 �I  e lut ion buffer was added. The extracted DNA was stored at -20 °C unt i l  used. 
DNA concentrat ion was determi ned by measuring the optical density (OD) at 260 
nm by using spectrophotometer (WPA Cambridge, UK). 
1 1.9. The poly merase c h a i n  react ion ( peR) 
PCR was performed by using PuReTaq Ready-to-Go PCR beads (Amersham 
Pharrnacia B iotech, Sweden). The procedure was carried out according to the 
manufacturer's instructions. 
PrUners of P53 and PC A genes were obtained from Pharmacia Company, USA. 
B RCA I primers were obtained from Operon B iotechnologies, Sweden .  Sequences of a l l  
primers used are l i sted i n  table 1 .  
For PCR ampl ification of PCNA, the reaction was performed with 2 .5� 1  of each 
primer at 1 0 pmol/� l ,  and d iethylpyrocarbonate-treated water (DEPC, ResGen. 
I nv itrogen, U SA) was added to a total volume of 25 � 1 .  The cycl ing program was as 
fol lows: predenaturation (95°C, 5min), 40 cycles of ampl ification through denaturation 
(950C, I m in), anneal ing ( 55°C, 1 m in), and extens ion (nOC, I min) .  A [mal 5 m inutes 
extens ion step was added i n  TECHNE/GENIUS thermal cycler. 
Material and Method 
Table 1 :  Primers u ed in peR reaction . 
Primers Seq uences An nea l i ng 
tem peratu re 
fC) 
PCNAfE I Forward : 5 ' -CTG GGA CAA CTT AAT GTT CCC-3 ' 5 5  
Reverse: 5 ' -TAG TGC A G C  TTA CTC TGC GC-3 ' 
BRCA l lE l l Forward: 5 ' -TIT CAC CCA TAC ACA TIT G-3 ' 4 8  
Reverse: 5 '  -CCT ITG CCA A T  A TT A CCT G-3 ' 
P531E5 Forward: 5 '-GAC C IT TGA ITC TIT CTC CTC TCC-3 ' 64 
Reverse: 5 '  -GGG AGA CCC TGG ACA ACC AG-3 ' 
P5 31E6-7 Forward : 5 '-CTG GTT GTC CAG GGT TCT CC-3 ' 64 
Reverse: 5 '  -CCC AAC CTG GCA CAC A GC IT-3 ' 
P5 3 1E8 -9 Forward: 5 '  -CTT ACT GCC TTG TGC TGT GC-3 ' 5 8  
Reverse: 5 '-CIT AAG GGT G A A  ATA ITC TCC-3 ' 
P53IE I O  Forward : 5 ' -GTA CTG TGA ATA TAC ITA CIT CTC C-3' 60 
Reverse: 5 ' -GGG CTG AGG TCA CTC ACC-3 ' 
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The P R ampli ficat ion of P53 exon was perfonned using 40 cycles of 
ampl i fication through denaturation (95°C, I m in); anneal ing for I min (see table 1 )  and 
e ten ion (n° , 1 m in) .  A final 5 minutes extension tep was added. The sequences of 
ynthetic primers used in the enzymatic ampl ification of p53 were according to 
Vancutsem et a l .  ( 1 994). 
PCR ampl ification of B RCA I exon 1 1  was performed with genomic DNA, 2 . 5 1l l  
of  each primers at 1 0  pmol/ll l ,  and DEPC water was added to a total volume of 25 Il l .  
For ampl ification, each sample was init ia l ly denatured a t  95°C for 5 m in, and then 
subjected to 40 cycles, each included denaturation at 95°C for I m in, anneal ing at 48°C for 
I min ,  and then extension at noc for 1 min .  An additional 5 min  was added for more 
extension at 72°C . 
1 1. 1 0. Aga rose gel electrophoresis 
From each PCR product 5 II I were added to 3 �l loading buffer contain ing 0.25% 
bromophenol b lue, 0 .25% xylene cyanol, 20% glycerol and I X  TBE buffer (90mM Tris 
base, 90mM Boric acid, 2mM ethylenedimethyltetra aceti c  acid PH 8 .4) and loaded into 
1 . 5% agarose gel .  The gel was run at 1 00 volts for 1 hour at room temperature. To 
determine the expected size of PCR products, 1 00 base pair ladder marker (Amersham 
B iosciences, USA) was used. The bands were v isual ized by sta ining the gel w ith 
ethid ium bromide ( 1 0  mg/m l) and exposing it to the UV trans- i l luminator 
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I I . l l .  i n gl e-st ra nd conform at ion poly m o r p h i s m  (SSCP) 
To detect po ib le  alterations in the nuc leot ides sequence of PC A and p53 
gene , the migration pattern of their PCR product on polyacrylamide ge l was analyzed by 
using the SSCP method. A 5 fl l of the PCNA or p53 PCR-products was denatured by 
add ing 5 II I load ing buffer containing formam ide, xylene cyanol and bromophenol blue 
and incubat ing at 96°C for 1 0  minutes. The mixture was immediately ch i l led on ice. 
Then, the denatured PC R products were loaded onto a 1 0% nondenaturat ing 
polyacrylamide gel and run at 60 volts for 4 hr at 4°C, using vertical e lectrophoresis cel l  
(B ioRad, USA).  
The s i lver sta in ing lcit (Amersham Pharmacia, Biotech, Sweden) was used to stain 
D A bands i n  the polyacrylamide gels .  The procedure was carried out accord ing to the 
manufacturer's instructions. Briefly, DNA in the gel s  was fIxed overnight by 0.6% 
benzene sulphon ic ac id. Gels were incubated in s i lver n i trate solution for 30 min .  DNA 
bands were v i sual ized by using a solution contain ing sodium carbonate, formaldehyde 
and sodium thiosulphate. The developed colour was stopped by using a mixture of 1 % 
acetic  aci d, 5% sodium acetate and 1 0% glycerol .  F inal ly, the stained polyacrylamide 
gels  were sealed and dried using cel lophane membrane (promega, USA). Computer 
scanning was performed by hp office jet 55 1 0  a l l - in-one (Hp image zone program).  
I l . 1 2. Restriction fragment length polymorp h ism ( RFLP) 
RFLP analysis was used to identify changes i n  the nucleot ide sequence of the 
peR product of B ReA 1 gene at the s ite where a restriction enzyme cuts. BamHI was 
used to cut the peR product of B RCA 1 .  The enzymat ic reaction inel  uded 3 fl l of l OX 
enzyme buffer E ( Prom ega, USA), 0 .3 fl \ 1 % bovine serum albumin (Promega, USA), 
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mixture was brought up to 3011 1  with DEPC-treated \ ater. A l l  samples were incubated 
overnight at 370C in block heater (Stuart c ient ific, U .K.) . The d igested products were 
loaded in nondenaturing 1 0% polyacrylamide gel for 2 hr at 1 1  OV at room temperature . 
Gels were stained in  the runn ing buffer ( I X  TBE) conta in ing eth id ium bromide ( 1 0 
mglml)  with continuous shaking for 2-3 hrs. Bands were visual ized by using the UV 
trans- i l luminator and photographed. 
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RESULTS 
CHA PTE R III 
R ES U LTS 
Re ult 
Throughout this study no change was detected in the general activ ity and body 
weight of DMBA- and DMBA-plus-alkaloid-treated rats as compared with control ones. 
The body weights of a l l  rats were est imated weekly and were with in the normal range of 
the orresponding age. No sign ificant d ifference was observed between the control and 
the treated rats. However 35% (7/20) of the 32- and 37-week-oJd rat treated with the 
crude e tract of Vinca alkaloids showed some alteration in their genita l  tracts manifested 
by the presence of vaginal blood. Such blood was not detected in control and DMBA­
treated rats. 
I I I . I .  M orphological  featu res of the  m a m m a ry gla nds in D M BA­
t rea ted rats 
Gross observation and gentle palpation of the mammary glands of control and 
DMBA -treated rats revealed the development of variable masses in about 29% of the rats. 
These masses were of variable sizes, and the covering skin appeared normal . They were 
prov isional ly considered to be tumors (Fig. 3 ) .  They developed in d ifferent topographical 
locat ions of the mammary glands; some were observed in the cervical region, others in  the 
thoracic and abdomino-inguinal regions. Nevertheless, these tumors were more frequent 
in the cervical region than in other regions (Table 2) .  
To confirm the nature of these tumors and to detect the early microscopic changes 
that occur during development of breast cancer, H&E stained t issue sections of a l l  the 
-annal appearance of mammary 
gland 
I 
t t C elllJ(:al tumor Ingu1I1al tumor 
Re sult s 
Fig. 3 :  DMBA-treated 42-week-old rat. Two tumors developed In cervical and 
abdomino-inguinal regions ( lower arrows) . 
Table 2 :  Tumors developed in DMBA-treated rats. 
Age group of rats 
32 weeks 37 weeks 42 weeks 47 weeks 
No. of rats 6 5 5 5 
Rats with  tu mor 1 t 3 1 
T u mor location Cervical - Cervical, thoracic and Cervical 
(in situ) abdomino-ingu inal 
Weight of t u m o r  1 5  No mass - No mass in 2 rats 3 
(gms) (in situ) (in situ) 
- 3 .2 ;  1 3 . 8 ;  3 ;  3 . 1 
Type of tu mor � Ductal sol i d  � In situ � Lactating adenoma � Squamous 
and cribriform cribrifonn � Ductal solid and cell papi l loma 
carcmoma carc inoma cribri form carcinoma 
� In situ � Papi l lary 
cribriform carcmoma 
carcinoma � In situ cribrifonTI 
carcinoma 
Results 
mammary glands of control and DMBA-treated rats were e amined. Microscopic 
exam ination of the mammary gland of control rats showed the normal ductal epithelial 
l in ing urround ing narrow lumen and external discontinuous layer of myoepithelial ce l ls. 
The latter were supported by some fibrous connective t issue which was surrounded by 
ma si e amount of adipocytes (Fig. 4). 
M icroscopic examination of a l l  mammary gland of rats treated with a s ingle oral 
do e of DM BA (80 mglkg body wt) revealed various degrees of morphological changes 
which is usua l ly  a combination of more than one abnormal pattern. Most of DMBA­
treated mammary glands had moderately  d i lated ducts with groups of smal l  ce l l s  in their 
lumens (F ig .  5 ) .  These free luminal ce l ls  had eosinoph i l ic  cytopl asm and smal l  
hyperchromatic nuc le i .  The e cel ls  were considered to be dead. In some other ducts a 
ign of increased secretory act i v ity was evident with the accumulation of homogeneous 
secretory materia l  in their lumens. Therefore, these mammary glands seemed to have 
unbalanced cel l  dynamics and enhanced secretory act iv ity. A l l  DMBA-treated rats had 
such changes in some of their mammary glands. Of the total number of DMBA-treated 
mammary glands examined (n=78) 46% were with al tered cel lu lar dynamics. 
The second type of lesion observed in the mammary glands of DMBA-treated rats 
was characterized by an i ncrease i n  the cel l  number which led to an apparent i ncrease in 
the density of the cel l s  forming the term inal ducts (Fig. 6). Mammary glands with these 
changes were referred to as hyperplastic .  However, those showing the previous l esions 
described in the former paragraph with a l tered cell dynamics were referred to as 
mammary glands in the stage of cel l  death. 
Hyperplast ic mammary glands also showed other smal l  ducts with signs of ce l l  
death and other pre-neopl astic lesions. These mammary glands with m ixed l esions 
represented about 39% of all DMBA-treated mammary glands examined (Table 3) .  
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Fig. 4 :  Nonnal  mammary gland of a control rat as it appear in a paraffin section stained 
with H&E. (A) The gland shows smal l  ducts surrounded by fibrous connective tissue 
(CT) and m uch adipose tissue (Ad). (B) H igher magn ificat ion of mammary gland duct 
showing d iscontinuous layer of myoepithel ia l  cel ls (arrows). Magn ification : x400 (A); 
x640 (B) .  
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Fig. 5 :  tage of cel l death in  the mammary gland showing early sign of  morphological 
change. otice the moderate d i latation of the ducts and presence of dead cel l s  in their 
lumen. Two ducts in the lower th i rd of the m icrograph show some secretory material in 
the i r  lumens. Magn ificat ion:  x400. 
Fig. 6:  Hyperp lasia as seen in a DMBA-treated rat. Note the increased number of 
term ina l  smal l ducts (arrows). Magn ificat ion: x400. 
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Table 3 :  umber of pre-neoplastic and neoplastic lesions developed in the DMBA-
treated and DMBA-plus-a lkaloids treated mammary glands. 
M a m m a ry  gla n d  lesions DM BA * D M BA -pJ us-a I ka loids * * 
Stage of cel l  death 36 (46%) 48(45%) 
Hyperplasia - 1 ( 1 %) 
Dysplasia I ( 1 .2%) -
Stage of cel l  death + Hyperplasia 2 1  (27%) 2 1  (20%) 
Stage of cel l  death + Dysplasia 4 (5%) 1 6 ( 1 5%) 
Stage of cel l  death + Hyperplasia + 8 ( 1 0%) 1 4  ( 1 3%) 
Dysplas ia  
I n  situ carcinoma + Stage of cel l  1 ( 1 .2%) 1 ( 1 %) 
death + H yperplasia + Dysplasia 
In situ carc inoma + Stage of cel l 1 ( 1 .2%) -
death + Hyperplasia 
Tumors 6 (8%) 3 (3%) 
*Total number of DMBA-treated mammary glands examined = 7 8  
* *Total number of DMBA-plus-alkaloids-treated mammary glands examined = 1 07 
Results 
The third kind of lesion observed was characterized by increased number of 
epithe l ial  duct cel l  which was man ifested with an increase in  the number o f  smal l duct 
and many of them showed an apparent increase in the secretory activity and accumu lation 
of ecretory materia l .  I n  the epithe l ia l  cel ls  of these ducts, many of the nucleol i  became 
prom inent. Mammary glands with these features were referred to as dysplastic (Fig. 7). 
Oy plastic mammary glands were developed in about 1 7% of a l l  exam ined DMBA­
treated mammary glands .  A few of these glands ( 1 .2%) showed on ly signs of dysplasia. 
The other were m ixed with s igns of ce l l  death and hyperplas ia (Table 3) .  
Two of the DMBA-treated rats (9.5%) developed large microscopic lesions made 
of d i  lated ducts which were most ly fi l led with cel ls. The nuclei of these cel l s  were 
variable in density and were frequently seen in mitosis. There were some spaces in 
between the cel l s  that formed secondary lumens. This lesion was typical of the cribriform 
type of carc inoma in situ (Fig.  8) .  I t  was estimated that 2 .4% of DMBA-treated 
mammary glands showed in situ cribriform carcinoma. These mammary glands also 
showed signs  of cel l  death, hyperplasia, and dysplasia (Table 3) .  
Advanced palpable pathological lesions were developed in 5 d ifferent rats and 
showed d ifferent h i stopathological features. These lesions were either ben ign or 
mal ignant. Benign lesions were developed in rats sacrificed at 42 and 47-weeks-old, with 
inc idence of 1 4% of the total number of tumors. The first type, lactat ing adenoma, was 
characterized by numerous round profi les. Lumens of these alveolar structures had 
serrated appearance due to decapitation or supranuclear vacuol ization of the l ining 
epithe l ium.  The size of these alveoli may increase due to accumulation of secreted 
material inside the l umens (Fig. 9). The other benign lesion, squamous cel l  papi l loma 
(Fig. 1 0), was developed in the 47-week-old rat. Ductal structures were maintained with 




Fig. 7 :  Dysplast ic DMBA-treated mammary gland. Note the d i l ated ducts (arrows) and 
decreased amount of connective t i ssue. Magnification:  x400. 
Fig. 8: In situ cribri form carcinoma in DMBA-treated rat showing local ized area of 
d i lated d ucts part ia l ly  fi l led w ith tumor cel ls .  Note the numerous peripheral m itotic 
figures (arrows) . Magni fication:  x400. 
3 5  
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Fig. 9: Lactat ing adenoma in DMBA-treated mammary gland showing numerous round 
profi les which m ay contain secretory material (arrow). Magn ification: x640. 
Fig. 1 0 :  Squamous cell pap i l loma i n  DMBA-treated rat showing multiple layers of 
ep ithel ia l  ce l l s  (arrows) . Magnification:  x200. 
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pre ence of kerat in and the decrease in the amount of connecti ve t issue ere typical 
features of th i s  tumor. 
I n  the DMBA-treated rat , mal ignant lesions were more frequent ( 1 9%) than 
benign les ions and were developed in one of the 32-week-old-rats and two of the 42-
week-old rats. The first type of mal ignant lesions observed was typical of invasive 
cribri form carc inoma. It  was characterized by sol id sheets of neoplastic epithel ia l  cel ls  
which were interrupted by round or irregularly shaped secondary l umens of variable s izes 
(F ig .  1 1 ) . I nd ividual neoplastic ce l l s  were moderate ly pleomorphic. 
The second mal ignant tumor observed was invas ive papi l lary carcinoma. It was 
characterized by numerous pap i l lary projections with th inner fibrovascular core. Papi l lae 
were l i ned by columnar ce l l s  that were cont inuous with a mult i layered and pleomorphic 
epithe l ium.  Mi tot ic  figures were frequently observed in th i s  tumor. Nucleo l i  appeared 
prom inent and often multiple (Fig. ] 2). 
ID . 2. E ffects of Vinca alka loids on the pre-neo plastic and neoplastic 
cbanges of the m a m m a ry glands of D M BA-treated rats 
To test whether the crude extract of Vinca alkaloids affects the morphology of 
nonnal mammary glands, some t issue sections of the mammary glands of alkaloid-treated 
rats were stained with H&E and examined with the l i ght m icroscope. No change was 
observed i n  the appearance of the mammary glands. The mammary duct system of 
a lkaloid-treated rats appeared s imi lar to that of the control rats shown in figure 4. 
When the extract of Vinca alkaloids was given into DMBA-treated rats the 
incidence of tumors was reduced to ] 5% compared with the 29% incidence in rats treated 
on ly with DMBA (Fig.  1 3) .  These tumors were developed i n  the thoracic and abdomino­
inguinal regions of the 32- and 37-week-old rats (Table 4). No tumors were developed in 
Re ult 
Fig. 1 1 :  I nvasive cribri fonn carcinoma developed in DMBA-treated rat. Note the sol id 
sheets of  ce l l s  i nterrupted by secondary lumina (anows). Magn ification: x200. 
Fig. 1 2 :  Pap i l lary carc inoma as it  appear in  a DMBA-treated rat. Notice the epithe l ial  
pap i l l ary growth w ith scanty connective t i ssue. Magnification: x200. 







Q,J 20% <:.J 
=: 1 5% Q,J 
"0 1 5% . -
<:.J 





Fig. 1 3 :  Tumor inc idence of DMBA-treated and DMBA-plus-alkaloids-treated rats. Note 
that treatment with Vinca alkaloids decreases tumor inc idence by about 50%. 
Table 4 :  Effects of Vinca alkaloids on the development of DMBA-induced 
mammary gland tumors . 
Age groups 
32-week 37-week 42-week 47-week 
No. of rats 5 5 5 5 
Rats with  tumor 2 I 0 0 
Tumor location - Thoracic Thoracic - -
- Abdom ino-inguinal 
Weight of tumor  - 2 .5  0. 1 4  - -
(gm) - 5 .6  
Type of tumor � In situ cribrifonn � Cribriform - -
carc inoma carcinoma 
� Cri bri fonn 
carc inoma 
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42- and 47-week-old rats. Howe er several rats deve loped hyperplastic (n= 1 3  out of 1 9  
rat : 68%) and dy pIa t ic (n= 1 2  out of 1 9  rats· 63%) changes i n  their mammary glands. 
Among a l l  exam ined mammary glands of DMBA-plus-alkaloids treated rats 45% showed 
pr m inent igns of cell death and 37% showed hyperplasia which was usual ly m ixed with 
ther pre-neoplast ic les ions (Table 3). Only one of the 32-week-old rats deve loped about 
5 gm tumor and, therefore, was sacrificed at 1 5  weeks. A l l  other mammary tumor masses 
developed ere very smal l  compared to tumors developed in DMBA-treated rats. 
Even though tumors developed after tTeatment with alkaloids tended to be smal l  
in  s ize, they were al l mal ignant. No benign lesions were developed except for the one 
appeared in the skin adjacent to the mammary gland . The first mal ignant lesion was a 
mix of two types: invasive cribri form and comedoform carcinoma. This tumor was 
characterized by mult i l ayered neoplastic epithe l ial cel l  growth interrupted by secondary 
lumens with variable shapes and sizes in addit ion to large central areas with necrotic 
debri s (F ig .  1 4A) .  The other tumors developed in the 32- and 37-week-old a lkaloid­
treated rats exh ibited the same histological features of cribriform carcinoma which 
appeared in DMBA-tTeated rats (F ig. 1 4B and C). 
I t  shou ld be mentioned that some mammary glands of the DMBA-plus-alkaloid­
treated 42- and 47-week-o ld  rats showed an increase in the amount of fibrous t issues i n  
the stroma. Also, 2 weeks before the p laned date of  sacrifice, one death was recorded in  
the 32-week-old group. Autopsy revealed no tumors and no obvious reason for death .  
An add itional group containing 4-rats was treated oral ly with the same dose of 
Vinca a lkaloids as i n  the second group for three weeks in order to check any sign of 
tox ic ity by observ ing the general behav ior and by exam ining mammary gland t i ssue 
sect ions. A l l  mammary glands exam ined appeared normal compared to the control 
mammary glands. 
Re ult 
Fig. 1 4 :  Light m icrographs of t issue sections obtained from rats treated with DMBA­
plus-alkaloids .  (A) Ductal sol id ,  cribriform and comedoform carc inoma. ecrotic 
cel l u lar debris C) and secondary l umens (anows) are typical features of th is  tumor. (B 
and C) Cribriform carc inoma developed in  32- and 3 7-week-old rats, respective ly .  
Magni fication : x200 (A) x400 (B), x640 (C) .  
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1 1 1 .3.  Im m u n o h i  toch e m ic a l loca l izat ion of P C N A  a nd BRCA I 
Irnmunolocal izat ion of PC A in the mammary glands of control rats revealed the 
presence of prol i ferating cells in some small term inal ducts (Fig. ] SA).  In add it ion 
PC A-labeled nuclei of myoepithel ial ce l ls in these control rats were occasionally 
ob erved ( inset in  Fig. I SA). The number of PC A-labeled cel ls  was counted per high 
po er field in  the mammary gland of al l  control and DMBA-treated rats examined. The 
PC A label ing index was then calculated, and averaged. Comparing the labeling indices 
in d ifferent pre-neoplast ic and neoplastic lesions developed in the mammary glands after 
treatment with DMBA revealed an increase in the number of PCNA-labeled cel ls  starting 
from hyperplasia, then dysplasia (F ig. l SC and D respectively) progressing to mal i gnant 
lesions (Fig .  1 6A and C). However, during stage of cel l  death, the PCNA-Iabel ing index 
was lower than that of control mammary glands (Fig. l S B; Table S) .  
In  mammary glands with palpable benign and mal ignant tumors the PCNA­
labe l ing indices were h igher than those in the control and other nonpalpable lesions. The 
PCNA labe l ing was h ighest in the case of cribdform carcinoma (Table S) .  
In rats treated with DMBA-plus-alkaloids, a decrease in PCNA label ing was noted 
dudng the stage of cel l  death s imi lar to that of the DMBA-treated rats. However, the 
labeling index of PCNA showed an increasing trend during progression from hyperplasia 
to cancer (Table 5). When the label ing ind ices for each type of lesion in DMBA-treated 
rats were compared with those of DMBA-plus-alkaloids treated rats, a sign ificant 
reduction in the PCNA label ing of the latter group was observed (P<O.OS) .  
When PCNA immunolabe l ing was examined in various mammary gland tissues of 
rats treated with DM BA or DMBA-plus-alkaloids and compared with labe l ing in t issues 
of control rats, some variation in the label ing intensities were observed. These t issue 
Results 
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Fig. 1 5 : PCNA labe l i ng i n  control mammary gland (A) and in early pre-neoplastic lesions 
developed in DMBA-treated rats (B-D) .  (A) PC A-labeled nuclei are seen in some 
epithe l ial duct ce l l s  of control mammary gland (arrow). In the inset, the nucleus of a 
myoepithel ia l  ce l l  expresses PC A (arrow head) . (B)  Stage of "cel l  death" lesion after 
DMBA treatment showing a few PC A-labeled cel ls  (arrows). otice increased 
secretory act ivity of the cel ls  w ith accumu lation PA -sta ined material in the lumen. (C) 
evere hyperplasia showing an i ncreased number of PC A-labeled cel ls .  (D) Dysplastic 
mammary gland of  a DMBA-treated rat . Notice the increased number of PC A-labeled 
cel l s  and accumu lat ion of secretory material in  the d i lated lumen. Magnificat ion : x640. 
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Ta ble 5: P A-label ing ind ices (means ± EM) estimated in normal t i ssues of control 
rat a wel l  as in variou pre-neoplastic and neoplast ic lesions developed in rats treated 
with DMBA or with DM BA-plu -alkaloids. 
PCN A-la bel i n g  i n d ices 
Ti ue D MBA DMBA-plus-alkaloids 
Con t rol 1 2 .3 ± 4 . 1 *  7 .5  ± 2 . 3 * *  
tage of cel l death 2 .3  ± 0.3 4 .7  ± 0.3 
Hyperp lasia 1 2 .7  ± 4 .2 5 ± 1 . 5 
Dysplasia 42 .7  ± 1 3 .9 23 .7  ± 1 0. 7  
in situ  cribr iform 64 . 5  ± 27.6 44.7 ± 1 1 .3 
Lactating adenoma 25 .3  ± 6.9 ND 
quamous cell pap i l loma 1 2 1 .3 ± 20.3 ND 
Papi l Jary carc inoma 1 20 ± 5 . 3  ND 
Cribriform carcinoma 1 79.7 ± 1 5 . 1  2 1 5 . 3 ± 1 8.2 
9 1 . 7 ± 9. 1 
49.7 ± 4 .5  
*Treated with corn oil only. 
* *Treated with alkaloids only. 
ND = not detected 
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secti n were pro e ed, cut, mounted. and immunoprobed together. o. ariation In 
P A label ing intensity was taken to reflect changes in the expression of PC A protein. 
Measurement u ing cion computer program revealed no s ign i ficant difference 
In P N A  label ing intensity in the lesions developed in DMBA-treated rat when 
compared with tho e of control rats. However, by comparing the intensity of PC A 
pr te in expres ion in the tumor developed i n  DM BA-treated rats with tumors developed 
after treatment with DMBA-plus-alkaloids, it seemed that the intensity of PC A 
immunosta in ing was decreased ( F ig. 1 6 ; A vs B and C vs D). Measurements showed a 
stat istica l ly  s ign ificant d ifference (P < 0 .05) between label ing intensity in DMBA-treated 
t i ssues and intens ity in DMBA-plus-alkaloids treated t issues (Fig .  1 7) .  
Immunohistochemical local ization of  BRCA I in  control rats showed that this 
prote in was present mainly in  the nuclei of some lum inal epithel ia l  duct cel l s  (Fig.  1 8A).  
Faint cytoplasmic stain was also observed in some smal l  ducts, which was more apparent 
in the large ducts. Early  m icroscopic lesions (pre-hyperplasia, hyperp lasia and dysplasia) 
deve loped in DMBA- and alkaloids-treated rats showed both nuclear and cytoplasmic 
local ization of BRCA I (Fig. 1 8B) .  The nuclear and cytoplasmic local ization of BRCA l 
was also noted i n  lactating adenoma and squamous cel l  papi l loma. However, in case of 
local ized and invasive carc inomas (in situ cribri form, cribriform and papi l lary 
carc inoma), B RCA 1 protein became mostly cytoplasmic (Fig.  1 8C). 
1 1 1.4. Expression of p53 protein  
Homogenized mammary gland tissue samples obtained from al l  control 
and treated rats were analyzed by Western blott ing to study the expression of pS3 protein 
during breast cancer progression and to test whether Vinca alkaloids has an effect on its 






Fig. 1 6 :  PC A expression in  DMBA-treated (A and C) and DMBA-plus-a lkalo ids­
treated (B, D) rats. (A) CribrifOlm carcinoma treated w ith DMBA shows h igher number 
of cel l s  expressing PCNA compared with contro l .  ( B) In cribriform carc inoma after 
treatment w ith a lkaloids, the expression of PC A is  down regu lated . (C) In situ 
cribri form carc inoma showing PCNA label ing in the periphery of d i lated duct (arrows). 
CD) Expression of PC A in cribriform carcinoma of alkaloids-treated rat showing low 
intensity of PC A labe l ing  compared with C (arrows) . Magni fication: x640. 
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Fig. 1 7 :  Bar p lot of PCNA intensity measured in four mammary gland lesions s imi lar to 
those shown in figure 1 6  (A-D) and plotted in the same order from the left: cribri form 
carc inoma of D M BA-treated rat (32-week-old rat) and in DMBA-plus-alkaloid-treated rat 
(32-week-old rat). in situ cribri form in DMBA-treated (3 7-week-old rat) and then in  
DMBA-plus-a lkaloid-treated (37-week-old rat) rats. Analysis of PC A intens i ty using 
student-I-test showed significant decrease in the intensity (p<0.05) of the lesions 
developed in 32-week-old  rats after treatment with alkaloids. 
Fig. 1 8 : Immunoreact iv i ty of B RC A 1 in  mammary glands of control (A) and DMBA­
treated rats (B  and C).  (A) ormal mammary gland of control rat e presses B RCA 1 
main ly i n  the nuclei  of duct epithe l ia l  ce l l s  (arrow) . (B) Dysplast ic mammary gland 
shows B RCA 1 in both the nucleus (arrow) and cytoplasm (arrow head) of epithe l ia l  cel ls .  
(C) Cribriform carc inoma showing mostly cytoplasm ic expression of B RCA 1 (arrow 
head) .  M agn i fication : x l  000 . 
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Fig. 1 9 :  Immunoblot analysis showing p53 expression in mammary gland t issues 
obtained from control rat (C; lane 1 )  and DMBA-treated rats with hyperplasia (Hyp; lanes 
2-4) and tumors (T lanes 5 -8). Lanes 9- 1 1  shows results from rats treated with DMBA­
plus- Vinca alkaloids (T+V).  The bottom panel shows immunoblott ing for the 
housekeeping prote in, act in,  to reflect the amount of prote ins loaded in each lane. 
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Re ult 
omparing to control ti ue (F ig. 1 9 ; lane 1 ), init ial  down regulation ill some 
hyperpla tic and beni gn lesion was ob erved (F ig. 1 9 ; lanes 2 and 5, respectively). As 
the mammary gland progre ses toward mal ignancy, the amount of p53 was increa ed. 
Th i s  was probably the mutant form detected by using ant i -p53 antibody clone PAb240 
(Fig.  1 9, lanes 3, 4 and 6-8) . 
Tumors obtained from DM BA-treated rats which a lso received Vinca alkaloids 
were analyzed for p53 prote in expression. The results showed that there was a tendency 
to detect only a small amount of p53 (F ig.  1 9; lanes 1 0  and 1 1 ) .  Only one tumor from 
rats treated with alkaloids showed high level of p53 (Fig.  1 9 ; lane 9). 
I I I .S.  Effects of D M BA or D M BA-plus-a l ka loids on PCN A, PS3 and 
BRCA I gen es i n  ra t m a m m a ry gla nds 
To test whether DMBA-treated rats with various pre-neoplastic and neoplastic 
mammary gland lesions developed m utations in PCNA, P53 and B RCA 1 genes, PCR­
SSCP and PCR-RFLP assays were used. 
Ampl ification of PCNA exon 1 yielded 230 base pair (bp) product (Fig .  20), 
which was analyzed for base change-induced mobi li ty shifts under undenatured condi tion 
of SCPo Control animals d isplayed the normal banding pattern of SSCP analysis, wh ich 
appeared as four main bands (F ig.  2 1 ). Admin istration of D M BA alone or w ith alkaloids 
did not induce any abnormal it ies in  the banding pattern of PCNA exon l .  
PCR products of P53 exon 5 revealed 270 bp ampJ icon for al l  samples when 
compared to the standard DNA molecular marker (Fig.  20). SSCP analysis of the 270 bp 
product of P53 exon 5 of control mammary glands showed two bands as indicated in 
figures 22  and 23 .  Out of 9 tumors, two of them (22%) exhibited band sh i ft  (three extra 
bands) w ith e lectrophoresis  in addition to the two bands appeared in control sample. 
Results 
Fig. 2 0 :  PCR products of PC A exon 1 ,  various exons of P53 and B RCA I exon 1 1  
analyzed by e lectrophoresis i n  1 . 5% agarose gel stained with eth id ium bromide. The flrst 
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Fig. 2 1 :  SSCP analysis of  the PCR products of PCNA exon 1 for control t issues (C), and 
tumors obtained from DMBA-treated (T) and DMBA-plus-alkaloids-treated (T+V) rats. 
Arrows ind icate main bands of PCNA exon 1 under SSCP. The first lane on the left (M) 









P53 exon 5 
T�2 
Fig. 2 2 :  CP analysis of the PCR products of P53 exon 5 in  control (C), DMBA-treated 
(T) and DMBA-plus- Vinca alkaloids-treated (N+V and T+V) rats. Not ice the loss of 
normal banding pattern in one DMBA-treated tumor (T32) .  The bands of the 
hyperplastic (N+V) and tumor (T+V) samples of the DMBA-plus-alkaloids-treated rats 
are s imi l ar to those of the control .  
P 5 3  exon 5 
c T32 Tn 
Fig. 23: SSCP analysis for P53 exon 5 showing bands shift in hyperplasia (arrow heads in 
lane Hyp42) and tumor samples (arrow heads in lane T32 and T42) compared to control 
pattern . Arrows indicate main SCP bands. 
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These two tumor were developed in the 32- and 37-week-old rats (Fig. 22 and 
23) .  In addition orne hyperplastic mammary glands showed simi lar band shift ing 
imi lar to that of tumor samples show n in figure 23 .  
Tumor ample of DMBA-treated rats which received Vinca alkaloids showed 
normal band ing pattern with no e idence of abnormal ity. The remaining samples sho'" ed 
banding pattern simi lar to that of control (Fig. 22 and 23) .  No hyperp lastic mammary 
gland e hibited abnormal band sh ift  in this group. 
peR ampl ification of exon 6-7 of P53 gene produced 300 bp band for al l  samples 
in agaro e gel ( F ig. 20). SSCP analysis d isplayed three bands representing the normal 
pattern of P53 exon 6-7. Analy is of DMBA-treated samples revealed bands simi lar to 
those of control with no shift detected in the polyacrylamide gels  (F ig. 24) . Normal 
banding pattern was also detected in rats treated with DMBA-plus-alkaloids. 
A l l  PCR products of P53 exon 8-9 from control and treated mammary glands 
showed single ampl icon indicated by agarose gel electrophoresi s at 350 bp (Fig. 20). I n  
Figure 25 ,  SSCP analysis of  P53  exon 8-9 showed two bands s imilar to the pattern of 
exon 5. This  fragment showed no difference in the mobi l ity among tumors and control 
before and after treatment with Vinca alkaloids. 
SSCP analysis of the 4 1 0  bp fragment of ex on 1 0  of P53 gene showed tv,ro main 
bands in the control mammary gland. Band shift was observed in  two tumors out of nine 
(22%) which were a l l  from rats treated w ith a lkaloids (Fig. 26 and 27) .  The number of 
bands and their position in the gel indicated DNA sequence variation. I n  figure 26, the 
sample i n  lane T+V32 shows two more extra bands while the sample in lane T+V31 
produced three extra bands as compared to control pattern of corresponding exon. 
Results 
P53 exon 6-7 
c T+Vn T+V3:! 
Fig. 2 4 :  The CP analysis of the P53 exon 6-7 PCR products of control tissue (C) and 
tumors of DMBA-treated (T42) and DMBA-plus-alkaloids-treated rats (T+V32 and 42). 
otice that there i s  no d ifference in the SSCP pattern in all samples obtained from treated 





P53 exon 8-9 
T+V25 
Fig. 2 5 :  The SSCP analysis of the PCR products from P53 exon 8-9 of co�trol tissue (C), 
and tumors obtained from DMBA-treated (T) and DMBA-plus-alkalolds-treated rats 
(T+V) .  
--======�================================= 5 3 
Result 
P53 exon 1 0  
c T-Vr 
Fig. 2 6 :  The CP analysis of the PCR products of p � 3  gene exon 1 0  of control t issue 
(C), and tumors obtained from DMBA-treated (T) and DMBA-plus-alkaloids-treated rats 







P53  exon 1 0  
T�2 
Fig. 2 7 :  SCP analysis of the PCR products of p53 gene exon 1 0  of tumors obtained 
from DMBA-treated (T) and DMBA-plus-a lkaloids-treated rats (T+V). Molecular 
marker ( I OObp) ind icates the s ize of resulted fragments. 
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Result 
The P R products of exon I I  of BR A 1 gene revea led more than one band on 
the gel (Fig. 28, lane und igested C). Therefore, we used RFLP method to detect the 
polymorphi m.  
Four d i fferent enzymes were used to find the appropriate cutter for BRCA I 
e. on I I  PCR product they are : XhoI , P Tl ,  BamHI ,  and EcoRl . Bam H l  was found to be 
the appropriate cutter for BRCA I fragment. PCR product of B RCA I exon I I  was at 
1 600 bp, which was the biggest size obtained using spec i fic primer sequence mentioned 
in the material and methods section . I n  figure 28, the digested products showed no 
remarkable d ifference between control and tumor samples. A l so, no d ifference was 
ob erved between tumors from rats treated with or without Vinca a lkaloids extract. 
Re ult 
BRCA 1 exon 1 1  
Digested 
T T-V 
Fig. 2 8 :  PCR-RFLP analysis of B RCA l exon 1 1  in tumors obtained from DMBA-treated 
(T) and DMBA-plus-alkaloid-treated (T +V) rats. Undigested band at 1 600 bp in lane C 
(from the left) represents B RCA I target product which was d igested with Bam H I  and 
produced two bands at 900 bp and 700 bp ( Janes digested C, T and T+V). A l l  samples 
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Discu sian 
In the present tudy, orne of the morphological and molecular change that occur 
during breast cancer development ha e been characterized in female Wistar rats treated 
ith a ingle dose ( 80 mg/kg body wt) of DMBA. orne of these DM BA-treated rats 
recei ed crude e tract of Vinca alkaloids to test whether it has an effect on the incidence 
of breast cancer and the early changes that occur during its progression. This  study was 
carried out with spec ial emphasis on PCNA as a cel l  cyc le protein, and p53 and BRCA 1 
a tumor uppressor genes. 
IV. l .  The seq uence of events that  occur d u ring  development of pre­
neop lastic les ions in D M BA-trea ted rats 
A series of microscopic changes have been observed in the mammary glands of 
DMBA-treated rats. The e changes are taken to be representative of the mult istep process 
that occurs before development of breast cancer. 
In the past, Beckmann et a l .  ( 1 997) described the first two stages of breast cancer 
development in humans as hyperplasia and carcinoma in situ. When Singh et a l .  (2000) 
induced breast cancer in Sprague Dawley rats with l -methyl- l -nitrosourea, hyperplasia 
was also the first h istopathological change observed. Even though these hyperplastic 
ducts of mammary glands are poorly studied, their presence has become a valuable 
indicator of mal ignant progression in  both humans and rats (Lee et aI., 2006; Weroha et 
aI . , 2006). 
In the DMBA-treated rats exam ined in th is study, some mammary glands 
deve loped hyperp lasia in assoc iation w ith other pre-neoplastic lesions (42 .4% of a l l  
Di cussion 
mammal) glands e amined in DMBA-treated rats) .  In a few mammary glands (2 .4%) 
carcinoma in situ a also obser ed . 
The majority of DMBA-treated mammary glands (93 .4%) exam ined in the present 
tudy developed another form of a h i stopathological change (Table 3). These glands 
e hibited moderatel d i lated term inal ducts characterized by numerous dead cel ls  
extruded into their  lumen (F ig. 5) .  This morphological change was observed either alone 
(46% of a l l  DMBA-treated mammary glands exam ined) or in association with other pre­
neopla tic lesions (47.4%). It is general ly bel ieved that when a cel l d ies, it releases some 
factor that st imu late neighboring post-mitotic ce l l s  to re-enter the cel l  cycle. I t  was 
reported earl ier that in lymphoid and vascu lar epithe l ial  tissues, apoptosis  precedes and 
leads to hyperplasia (Volkmann et aI . ,  1 996; lzumi et a I . ,  2003) .  Thus, the stage of cel l  
death described has been considered to occur earlier than hyperplasia, and taken to be the 
first stage in the mult istep process of breast cancer development in the DMBA-treated 
Wister rats. 
Dysplasia of the mammary glands is the third pre-neoplast ic lesion detected in the 
DMBA-treated rats. Dysplasia appeared either alone ( 1 .2%) or, more commonly ( 1 8 .2%) 
in association with other pre-neoplasti c  lesions (Table 3). Simi lar features of this lesion 
were also descri bed by Xie et a!. ( 1 999) when breast cancer was induced in rats with a 
combination of ] 7�-oestradiol and testosterone. 
It has been reported earl ier that pre-neoplastic changes of the mammary gland 
inc ludes intraductal noninfi ltrating carcinoma, or carcinoma in situ (Komitowski et a! . ,  
1 982). In  the present study, 9 .5% of the rats treated with DMBA developed intraductal 
non infi ltrating carcinoma in situ. When all the DMBA-treated mammary are considered, 
it is estimated that carc inoma in situ occurs in only 2 .4% of them. It occurs in association 
with other pre-neop lastic lesions (Table 3). It has already been shown that DMBA 
Discus ion 
treatment alter the normal process of mammary gland d i fferentiation of term inal ducts to 
al eol i  and lobu les, producing instead the sequence of terminal ducts � intraductal 
pro l iferat ion � carcinoma in situ � invasive carcinoma (Russo et aI . ,  1 982). Extensive 
tudie on the unique features of in situ carc inoma reveal its sign ificance in pred ict ing the 
aggressiveness of brea t cancer ( Lennington et a I . ,  1 994 ; Rehman et a I . ,  2000). 
I V. 2 .  Tu mors developed in the  m a m m a ry gla nds of D M BA-t reated 
Wister rats a re mostly mal igna nt.  
I n  this study, the inc idence of mammary tumors which was induced in Wistar rat 
using DMBA is  29%. I n  contrast, Bojkova et a l .  (2000) found that administration of 20 
mg of DMBA in Wistar :Han rats resulted in about 8% tumor i ncidence. Repeated 
DMBA administration (3 doses of 1 0  mg/rat) increased the inc idence to 85%. When the 
more sensitive Sprague Dawley rats were admin istered with the same single dose of 
DMBA, they showed h igher inc idence of tumor development, 46 and 67%, which 
reached up to 1 00% with mult iple doses (Kubatka et aI . , 2002). 
These d ifferences in rat susceptibi l ity cou ld, poss ibly, be due to the age when the 
carcinogen was admin istered. The incidence reached the highest rate between postnatal 
days 40-46, when cel l s  of the tenninal ducts have maximal pro l iferative act ivity. The 
physiological changes through seasons may also play a substantial ro le in determin ing the 
suscept ib i l ity to carc inogenesis (Kubatka et aI . , 2002). A l l  rats used in the present study 
received DMBA at almost the same age and during the same season. 
The vast majority of tumors observed in DMBA-treated rats of the present study 
are carcinomas (Table 2). This is consistent w ith previous studies using DMBA or 1 -
methyl - l -n i trosourea as a carcinogenic agent (Russo and Russo, 1 996; L iska et aI . ,  2000; 
Costa et aI., 2002). 
Discussion 
The most h igh ly mal ignant tumors in the rat have some common features with the 
in fi ltrating ductal carc inoma of the human (Russo et a ! . ,  1 990c). I n  th is study, two 
d i fferent forms of carcinoma were observed :  cribriform and pap i l lary; the former has 
been ob erved more commonly. However, Russo and Russo (2000) reported that 
In a ive papi l lary carc inoma is the most typical and frequent DMBA-induced tumor. 
Two other form of tumors are also observed in the present study and c lassified as 
" benign " .  They include:  I )  lactat ing adenoma which was previously identified and wel l  
characterized ( Russo and Russo, 2000; Costa et aI . ,  2002), and 2)  squamous cel l  
papi l loma which i s  identified in the present study in DMBA-treated rats for the first t ime.  
Based on the features described in the results sect ion, i t  is hypothesized that the origin of 
quamous cel l  papi l loma i s  probably the lact iferous or large ducts which are c lose to the 
n ipp le. 
Wh i le ben ign tumors of the mammary glands that occur in the rats c losely 
resemble those of humans, they are observed more frequently in humans than in  rats 
treated with I -methy- l-n itrosourea (Russo et a ! . ,  1 990b; S ingh et a I . ,  2000). However, 
L iska et al . (2000) were not able to detect any ben ign tumors by using simi lar carc inogen 
in rats. I n  the present study, ben ign tumors are observed less frequently than mal ignant 
lesions. It is postu lated that the Jess d ifferentiated terminal ducts develop invasive cancer 
lesions when attacked by DMBA, whi le ben ign lesions such as adenomas arise from the 
more d i fferentiated big ducts (Russo et aI . , 1 990b). If this is the case, then the reason of 
deve loping more carcinomas than ben ign lesions could simply be due to the structural 
organ ization of the tree-l ike branching duct system of the mammary gland in which the 
sma l l  termina l  ducts are much more numerous than the big ones. 
Discu sian 
I V.3. A n  i n it ia l  decrease fo l lowed by a gra d u a l  increase in cel l  
prol iferation featu res b reast ca ncer development i n  D M BA-treated rats. 
PC A has been described as one important predictive and prognostic factor which 
is  u ed widely as a marker for ce l l  prol iferation i n  the c l in ical assessment of various 
tumors inc lud ing breast cancer CWu et aI . ,  2003). In the present study, the PC A­
labe l ing has al 0 been u ed to corre late the rate of cel l  pro l i feration with each of the 
various pre-neoplastic and neoplast ic changes observed in DMBA-treated rats. 
The nuclear expression of PCNA in the mammary glands of control rats shows 
that cel l  pro l i feration is mainly found in the smal l  term inal ducts. This finding confmns 
previously pub l i shed data (Qiu e t  a I . ,  2005). The occasional presence of  PeNA-labeled 
m oepitbe l ial  cel l s  ind icates that these d i fferentiated cel ls  mainta in  some capacity for 
mi tosis (Fig .  I SA). 
In D MBA-treated rats, progression toward breast cancer is found to be associated 
wi th an increase in the number of peNA-labeled cel l s  start ing at the stage of hyperp lasia 
(Table 5). Thi s  observation corre lates with those of Funakoshi et a J .  (2000) who studied 
cani ne mammary gland tumors. However, unexpected ly, there was a reduction in peNA 
labe l ing during the in i t ial  stage of "cel l  death". This m ight be related to the deregu lation 
phenomena of neopl astic  progression (Hoshino, 1 992). 
In an attempt to evaluate the corre lation between breast cancer progression and the 
intensity of PCNA labe l ing, quantitative measurements were carried out using Scion 
image program. I t  is general ly not iced that the intensity of sta in ing gradual ly increases 
wi th progression toward breast cancer. S imi larly, Mo et a l .  (2004) reported that the 
express ion of peNA was sign ificantly related to progression of nasopharyngeal tumor in 
humans. However, Surowiak et a l .  (2005) used another pro l i feration marker, K i -67, and 
Di cussion 
found it useful III correlating its labe l ing intensity with the grading of ductal breast 
cancer. 
I V.4.  A lteration of p53 d u ri n g  development of breast cancer in rats 
P53 i a tumor suppressor gene which has an apparent role in the development 
breast cancer in humans, m ice, and rats (Hol lstein et a I . ,  1 99 1 ;  Ol ivier et a l . ,  2002 ; Zurer 
et a l .  2004). In the pre ent tudy, the expression of p53 protein was stud ied in a l l  lesions 
obta ined from DMBA-treated rats using mouse monoclonal antibody, PAb-240 clone. 
This  ant ibody detects both wi ld-type and mutant forms of p53 (Gannon et a1 . ,  1 990). The 
resu lts reveal that p53 is d ifferential ly expressed during breast cancer progression. It i s  
down-regulated i n  pre-neoplastic lesions, but up-regulated in mal ign ant tumors. Lee et a l .  
(2004) reported the sign ificant corre lation between p53 mutations and p53 over­
expression . A lso it was reported that p53 prote in expression in  benjgn tumors is much 
less compared to that in  mal ign ant l esions. By using the same c lone of ant ibody, 
upregulation of the mutant form of p53 is observed in the advanced stages of human 
breast cancer (Andersen et a1. 1 993). These results are consistent with the data obtained 
in the present study. 
The correlation between p53 accumulat ion and the increase in tumor cel l  
pro l iferation has been also demonstrated i n  the present study. Therefore, as previously 
reported, it seems that p53 negatively regulates cel l  d iv ision and its mutation leads to 
aberrant regulation of cel l  pro l iferation ( Kesari et al., 1 997). 
An increasing number of studies are using molecular methods to analyze P53 
mutations in  cancer t issues. Mutations in p53 gene are very common in human cancers · 
they occur i n  20-40% of breast cancer cases ( Kalemi et a l . ,  2004) . I n  comparison to 
brea t cancer, 50% of adult cancers such as colon, stomach, I i  er and others are also 
characterized by p53 mutat ion (Jerry et a I . ,  2000). 
Most of the P53 mutat ions reported in  d i fferent types of tumors are c lustered 
w ith i n  exons 4-8, which encode a h ighly conserved region, conta ining the DNA binding 
domain of the prote in  (Jerry et a I . ,  2000). I n  the present study four of the exons of p53 
gene (exon 5, 6-7 8-9 and 1 0) were studied for poss ible mutations that may occur during 
brea t cancer development . It was possible to detect P53 polymorphi sm in  some rats with 
hyperp lastic mammary glands using SSCP technique (Fig. 23) .  The present results 
corre late w ith tho e of Keohavong et al . (2004) who reported P53 mutat ions i n  
indiv iduals with pre-invasive mammary gland lesions: atypical ductal hyperplasia and 
ductal carc inoma in situ. In mice, Jerry et al. ( 1 993) also reported over-expression of p53 
and its mutat ion in  hyperplastic mammary glands. 
It has been est imated that 3 3 .3% of the tumors analyzed in the present study show 
polymorphism in P53 exon 5. In the DMBA-treated rats, base substi tutions at A or 0 i n  
the  sense strand of the  cDNA accounted for 95% of a l l  the point mutat ions of P53 gene 
( Manjanatha et a I . ,  1 996). The predominance of purine (A or G) mutations is consi stent 
w ith the fact that DMBA-adduct formation preferent ia l ly occurs on dA and dO 
(Manjanatha et aI . ,  1 996) lead ing to depurination (Chakravarti et aI . ,  1 995).  
I V.S.  B lockage of B RCA I t rans locat ion d u ri n g  development of b reast 
ca n cer  in DMBA-t reated rats 
In the present study, BRCA I local ization us ing i mmunoh istochemistry revealed 
nuclear expression in luminal  epithe l ia l  duct cells. Progressive h istopathological changes 
toward breast cancer are assoc iated with a l teration in nuc lear local ization of BRCA l unt i l  
i t  becomes cytoplasm ic i n  mal ignant tumors. S imi lar cytoplasmic local ization of BRCA l 
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in brea t carcinoma was detected in studies conducted in humans using the same clone of 
the ant ibody (Chen et a I . ,  1 996; chofield et al . 2000). By using d ifferent ant ibodies 
pec ific for BRCA l ,  s imi lar resu lts were obtained . Feng et a l .  (2004) reported increased 
amount of cytoplasmic expression of B RCA I in breast cancer ce l ls after exposure to 
ion izing rad iat ion, uggest ing a role played by p53 in the al teration of this translocation 
process. It has been proposed that e l im ination of BRCA 1 from the nuc leus may be 
required for the cel l  to stop div id ing in response to DNA damage to avoid genomic 
in  tabi l ity ( Feng et aJ . , 2004). 
I n  order to examine whether B RCA I gene has been altered, RFLP technique was 
used . I n  the present study no mutation has been detected in exon 1 1  of B RCA I gene of 
a l l  rats examined. Therefore, based on these resu lts and those avai lable in the l iterature 
(Lee et a I . ,  1 999), it seems that a l teration of B RCA 1 local izat ion may be due to 
abnormal ity of molecules involved in the transport rather than mutation of the B RCA I 
gene itse lf. Feng et a l .  (2004) reported that DNA damage cause breast cancer progression 
that is  associated with the production of an inactive form of B RCA 1 .  The latter can not 
be targeted to the nucleus and, therefore, remains in the cytoplasm of cancer ce l l s .  Thus, 
impairment of the nuclear local ization signal and/or the nuc lear export signal  of B RCA I 
protein are possible explanations for the abnormal cytoplasmic local ization of B RCA I 
during breast cancer progression . 
I V.6. I n h ibit ion of breast cancer p rogressio n  in  rats by Vinca alka loids 
The DMBA-induced cancer model has been used extensively to test the 
preventive and curative potent ia l  of a variety of chemical compounds (Himes, 1 99 1 ;  
Rajeshkumar et aI . ,  2005 ;  Kotsopoulos et aI . ,  2005 ; Lai and S ingh, 2006). I t  has been 




inh ibi tory effect on breast cancer progression . ui and Fan (2005) found that Vinca 
alkaloid (v incristine and inblastine) alter some D A-binding proteins, which in tum 
inhibited ce l l  cyc le progre sion. Other studies reported that Vinca alkaloid (vincri st ine 
and vinorelbine) may induce bcl-2 phosphorylation, and therefore inhibit ing its 
ant iapoptot ic activity (Pathan et al. 200 I ,  Wang et a l . ,  1 999). Recently, Martinez-Campa 
et a l .  (2006) attributed the effect of Vinca alkaloids (vincristine vinblastine and , , 
v inorelbine) to decreased expression of estrogen receptor alpha protein and its mRNA 
levels in the human breast cancer cel ls .  
In addit ion to the effects of a single alkaloid on the progression of breast cancer, 
we hypothesize that a combination of more than one alkaloid may have a synergist ic 
effect and become more effective in  the inhibition of breast cancer cel l  growth. 
Grover et aI . ,  2002 reported that oral adm in istration of 200 mg/kg body wtJday of 
crude extract of the areal parts of Vinca rosea plant for several weeks has no toxic effect 
on the rats .  I n  the present study, the same dose, 200 mg/kg body wt, but of a crude Vinca 
alkaloids extracted from the areal parts of Vinca rosea has been introduced into rats 
during the i n jtiation phase of breast carc inogenesis ( 7  days post DMBA administrat ion). 
An inhibi tory effect on the tumor development has been observed. On ly ] 5% of the rats 
developed tumors, i .e .  50% less than what developed in DMBA-treated rats. Tumors 
appeared after a lkaloid t reatment were not only few in number, but were a lso very smal l  
i n  s ize (2 .5  and 0. 1 4  gm). 
I t  seems that the early treatment during the in i tiation phase of breast cancer 
development is crucia l .  Rao et a l .  ( 1 985) reported that an extract prepared from the 
leaves of Piper belle blocks the progression of the neopl astic progression in DMBA-
treated rats. In contrast, treatment of the rats with the same extract at a later phase after 
development of tumors d idn 't show any significant inhibit ion in tumor growth. S im i lar 
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resu lts were al 0 ob erved b Russo et a l .  ( 1 990a). The found that earl adm inistration 
of chorion ic gonadotropin for 2 1  days into DMBA-treated rats decreased the inc idence of 
mammary tumors. The e resu lts were attributed to the abi l ity of chorionic gonadotropin 
to induce pS3-dependent programmed cell death in tumor cel l s  (Srivastava et aI., 1 997). 
However Rao ( 1 98 1 )  found that exposure of virgin female rats to asparagus-root-extract­
d iet before the adm inistration of DMBA was associated with a reduction in the inc idence 
of mammary tumors. Th is effect was due to enhanced d ifferentiation of terminal ducts 
which, therefore, became less susceptible to carcinogenesis. 10 the present study, an 
attempt has been made to provide some explanation for the inhibitory effects of crude 
Vinca alkaloids on the incidence of breast cancer by examining some genes involved in 
ce l l  cycle  regulation. 
Wh i le immunoh istochemistry and RFLP analysis revealed no effect for Vinca 
alkaloids on the prote in  product and DNA sequence of BRCA l gene, protein products of 
both PCNA and pS3 genes appeared to be d irectly or indirectly affected by these crude 
a lkaloids. 
IV.6. 1 .  T reatment with  Vinca alkaloids down-regulates PCNA expression in DMBA­
t reated rats 
I t  is wel l known that ant ibodies specific for PCNA can be used as a useful ce l l  
prol i feration marker to assess the effectiveness o f  cancer therapeutic agents (Denoyel l e  et 
aI . , 2003;  Thangapazham et a ! . ,  2006). Aziz et a 1 .  (2005) reported that PCNA expression 
corre lates positively with tumor s ize and h istological d ifferentiation of the mammary 
gland . A l so in  colon cancer, Zhou et a l .  (2000) found that the decrease in the s ize of 
tumors induced by I -methyl- l -n itrosourea correlate with the decrease in the amount of 
PCNA l abeled cel ls .  10 the present study, administration of Vinca alkaloids to DMBA-
treated rats induced an effective inhibitory action on PC A protein  expression in  the 
mammary gland . Counts of PC A-labeled cel ls in each of the pre-neoplastic and 
neoplastic mammary gland lesions de e loped after DMBA-plus-alkaloids treatment are 
sign ificant ly lower than those in rats treated on ly with DMBA. I n  add it ion, the label ing 
intensity of PCNA in the nuclei showed significant decrease in some tumors developed in 
the alkaloids-treated rats. Therefore, the decrease in both the PCNA labe l ing indices and 
its amount, as mea ured by immunohistochemistry, may explain the smal l  tumor size 
observed in some alkaloids-treated rats. 
The inhib itory effect of Vinca alkaloids on PCNA expression has been expla ined 
by B lajeski et a l .  (2002), who stated that microtubu le-disrupting agents, which thought to 
arrest cel ls  in m itosis in itiate a cascade of events involving upregulation of p2 1 leading to 
inh ibition of Cdc2-cycl in  B complex and PCNA, preventing interaction of the latter with 
other components of the DNA polymerase complex. 
In spite of the changes observed at the level of PCNA protei n, no polymorph ism 
has been detected in exon 1 of PCNA gene using PCR-SSCP analysis for both DMBA­
treated and DMBA-plus-alkaloids treated rats. In 1 998, Bechte l et a l .  a lso found that 
al teration of PCNA during cancer development was not associated w ith genetic mutation. 
However, the contribution of altered PCNA in  the accumulation of genetic mutat ions and 
genomic instabi l ity was not exc luded. 
I V.6.2. Vinca a l ka loids dow n-regu la tes expression of m uta nt  p53 p rotei n in DMBA­
treated rats 
A lteration of p53 expression and i ts mutation are common events that occur 
during cancer development. In the present study, the reduction in the inc idence and size 
of the DMBA-induced tumors in the mammary glands of Vinca alkaloids-treated rats is 
Discu ion 
a so iated with a reduction in p53 protein expre sion in two of the three tumors detected. 
The amount of p53 protein detected by Western blot analysis becomes more or less 
imi lar to that of control mammary glands (Fig. J 9). Therefore, the reduction in PC A­
label ing in Vinca alkaloids-treated rats is associated with down-regulation of p53 
express ion . These resu lt are in agreement w ith those of Korkolopoulou et a l .  ( 1 994) who 
found s imi lar correlation between p53 expression and PCNA label ing indices. One may 
hypothesize that treatment with the crude extract of Vinca alkaloids inhibits the 
accumu lation of mutant p53 protein in the cel 1s during progression to breast cancer. Th is 
assumption cou ld be supported by Schwartz and Shk lar ( 1 996), who reported that 
carotenoids and ret inoids prevent DMBA-induced mal ignant transformation in vitro by 
inhibit ing expression of the mutant form of p53 and enhancing the tumor suppression 
function of p53 .  
When Vayssade e t  al . (2002) exam ined the effect of  the Vinca alkaloid 
incristine, on breast cancer cell l ines, up-regu lation of p53 - inducible genes was observed 
along w ith some increase in p53 m RNA and protein levels. Therefore, wi ld-type p53 
fac i l itates the response to ant i-microtubule agents which increase the expression of p53-
associated proteins, such as p2 1 ,  1 4-3-30, GADD45,  and bax. These proteins are known 
to be involved in cel l  cyc le  arrest, apoptosis or DNA repair (Vayssade et aI . ,  2002). 
Summary & Conclusion 
S U MMA RY & C O N C L US ION 
] n  th i s  study, a erie of h istopathological changes were induced in the mammary 
glands of W i  ter rats by administering a single oral dose of DMBA. These changes 
appeared to be repre entat ive of the variou pre-neoplastic and neoplastic events that 
occur during breast cancer development. Alteration of cel lu lar dynam ics leading to 
enhanced cel l  death was the first pre-neoplast ic event observed .  Thi s  was fol lowed by 
hyperplast ic and dysplastic changes leading to carc inoma in situ. Malignant lesions 
appeared in two forms cribriform and pap i l lary carc inomas and were more common than 
ben ign tumors : lactat ing adenoma and squamous ce l l  papi l loma. 
These morphological changes were associated with alteration in the expression of 
P A p53, and BRCA I proteins .  An init ia l  down-regu lation fol lowed by up-regulation 
In the expression of both PCNA and p53 fol lows the sequence of the morphological 
changes. Th i s  was assoc iated with polymorphism of exon 5 of the p53 gene. Whi le no 
change in the level of BRCA 1 protein  was detected, i ts translocation from the cytoplasm 
to nucleus was blocked during breast cancer progression. 
By using a crude extract of Vinca a lkaloids, it was possible to reduce the number 
of neoplastic lesions developed in DMBA-treated rats. These few lesions were smal l  in 
s ize and were characterized by inh ibition of PCNA expression and reduction in the 
amount of p53 mutant form. 
I t  i s  very l ikely that the observations reported in the present study are appl icable to 
humans because : 1 )  the overa l l  organization of the epithe l ia l  duct cel l s  of rat mammary 
glands are comparable to those of the human, 2) DMBA is a wel l  known environmenta l  
factor that may contribute to the etiology of  breast cancer in humans, 3)  most of  the 
h istopathological changes observed in the mammary glands of DMBA-treated rats are 
sim i lar to those reported in humans and 4) the three genes examined in this study are 
Summary & Conclusion 
h ighly conserved among mammal ian species. Therefore, one of the important chal lenges 
no is to know whether this very early stage of pre-hyperp lastic ce l l  death occurs in 
human . Then to use gene profi l ing technology to pinpoint some genes that could be 
usefu l  a early markers for screening women susceptible to develop breast cancer. 
Final ly, th is genetic approach cou ld also help pharmaceutical companies to design 
therapeutic and/or preventive agents against breast cancer. 
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